

CITATION REPORT

List of articles citing

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

DOI: 10.1136/bmj.324.7329.71

BMJ: British Medical Journal, 2002, 324, 71-86.

Source: <https://exaly.com/paper-pdf/34035376/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2308	Aspirin for the next generation. 2013 , 7, 300		3
2307	Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011. 2012 , 6, 245		1
2306	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. 2001 , CD003333		8
2305	Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. 2001 , CD002130		12
2304	Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?. 2002 , 106, 379-85		132
2303	Statins and renal function. 2002 , 53, 493-502		83
2302	Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). 2002 , 106, 1909-12		102
2301	Need to test the arterial inflammation hypothesis. 2002 , 106, 136-40		106
2300	Considering Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 2002 , 2, 187-188		
2299	Use of statins and aspirin to reduce risks of cardiovascular disease. 2002 , 7, 77-80		15
2298	Aspirin for the primary prevention of coronary events. 2002 , 347, 948; author reply 948		0
2297	Aspirin with bypass surgery--from taboo to new standard of care. 2002 , 347, 1359-60		31
2296	Can we image the "active" thrombus?. 2002 , 22, 1753-4		10
2295	Review: Which patients with diabetes should receive which antiplatelet agents?. 2002 , 2, 157-160		0
2294	Vascular viewpoint. 2002 , 7, 157-158		
2293	Acute pulmonary embolism: don't ignore the platelet. 2002 , 106, 1748-9		41
2292	Evidence-based risk stratification to target therapies in acute coronary syndromes. 2002 , 106, 1588-91		44

2291	Clopidogrel plus aspirin for stroke prevention. 2002 , 33, 2546-7; author reply 2546-7	11
2290	A Practical Guide to Understanding the 2002 ACC/AHA Guidelines for the Management of Patients With Non-ST Segment Elevation Acute Coronary Syndromes. 2002 , 1, 129-149	
2289	Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?. 2002 , 33, 1723-6	33
2288	Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. 2002 , 13, 645-51	7
2287	A Practical Guide to Understanding the 2002 ACC/AHA Guidelines for the Management of Patients With Non-ST Segment Elevation Acute Coronary Syndromes. 2002 , 1, 129-149	
2286	Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. 2002 , 14, 225-30	18
2285	Aspirin and cancer risk: an update to 2001. 2002 , 11, 535-42	40
2284	Aspirin in the prophylaxis of coronary artery disease. 2002 , 17, 552-8	32
2283	Article makes simple errors and could cause unnecessary deaths. <i>BMJ: British Medical Journal</i> , 2002 , 324, 167	18
2282	Preventing atherosclerotic events with aspirin. <i>BMJ: British Medical Journal</i> , 2002 , 324, 103-5	28
2281	Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. 2002 , 20, 2301-7	48
2280	Confounding by indication in epidemiologic studies of commonly used analgesics. 2002 , 9, 199-205	134
2279	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. 2002 , 106, 388-91	1349
2278	The vulnerable plaque and acute coronary syndromes. 2002 , 113, 668-80	82
2277	Clinical practice. Transient ischemic attack. 2002 , 347, 1687-92	136
2276	Aspirin chemoprevention is beneficial for those at increased risk of cardiovascular events. 2002 , 6, 103-104	
2275	A benefit-risk assessment of agents used in the secondary prevention of stroke. 2002 , 25, 943-63	3
2274	Aspirin and mortality from coronary bypass surgery. 2002 , 347, 1309-17	557

2273	Warfarin, aspirin, or both after myocardial infarction. 2002 , 347, 969-74	693
2272	RC-529 improves efficacy of hepatitis B vaccine. 2002 , &NA;, 11	
2271	From the World Literature. 2002 , 2, 59-67	
2270	Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. 2002 , 107, 45-9	150
2269	Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. 2002 , 108, 115-9	54
2268	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 2002 , 360, 7-22	658 ₁
2267	Two decades of progress in preventing vascular disease. 2002 , 360, 2-3	28 ₁
2266	[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]. 2002 , 55, 975-86	8
2265	Modificaci3n de los factores de riesgo en el paciente arterioscler3tico joven: mecanismos implicados. 2002 , 54, 174-181	
2264	[Prognosis of diabetic patients with ischemic cardiopathy]. 2002 , 55, 751-62	8
2263	[2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction]. 2002 , 55, 631-42	48
2262	Aspirina en la prevenci3n primaria del paciente hipertenso. 2002 , 202, 652-654	1
2261	Aspirin for the primary prevention of cardiovascular events. 2002 , 177, 343-4	3
2260	Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction. <i>BMJ: British Medical Journal</i> , 2002 , 324, 59-60	9
2259	Management Following Myocardial Infarction. 2002 , 30, 76-80	
2258	Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. 2002 , 89, 26D-32D	93
2257	Aspirin beyond platelet inhibition. 2002 , 90, 39-41	12
2256	Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). 2002 , 90, 358-63	435

2255	Seeking the optimal aspirin dose in acute coronary syndromes. 2002 , 90, 622-5	34
2254	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. 2002 , 90, 625-8	314
2253	Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). 2002 , 90, 760-2	57
2252	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. 2002 , 90, 11i-21i	251
2251	Treatment of peripheral arterial disease. 2002 , 4, 26-40	7
2250	The public health potential of aspirin. 2002 , 91, 49-50	11
2249	Scientific Surgery. 2002 , 89, 506-506	
2248	Measurement of thrombosis and its prevention. 2002 , 54, 96-100	9
2247	Inflammation and infection in clinical stroke. 2002 , 22, 1399-419	212
2246	The efficacy and safety of perioperative antiplatelet therapy. 2002 , 13, 97-103	30
2245	Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. 2003 , 16, 119-28	20
2244	Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. 2004 , 57, 188-98	29
2243	Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. 2003 , 42, 851-7	27
2242	Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. 2003 , 26, 358-64	6
2241	Acetosal ter discussie?. 2003 , 41, 98-100	
2240	Dipyridamol voor secundaire preventie van arteriële accidenten. 2003 , 46, 526-527	1
2239	Acute Myocardial Infarction: Antithrombotic Therapy. 2003 , 5, 3-11	
2238	Atherosclerotic Carotid Artery Occlusion. 2003 , 5, 501-509	13

2237	Atherosclerotic Carotid Artery Occlusion. 2003 , 5, 381-389	
2236	Antithrombotic and thrombolytic therapy for ischemic stroke. 2003 , 5, 267-75	0
2235	New strategies for prevention of ischemic stroke: the LIFE study. 2003 , 3, 46-51	2
2234	Crystal structure of Enterobacter cloacae 908R class C beta-lactamase bound to iodo-acetamido-phenyl boronic acid, a transition-state analogue. 2003 , 60, 1764-73	18
2233	Carotid stents: is the gold standard ready for change?. 2003 , 21, 132-138	1
2232	Increased platelet aggregation and activation in peripheral arterial disease. 2003 , 25, 16-22	81
2231	The role of platelets in peripheral vascular disease. 2003 , 25, 6-15	46
2230	Antiplatelet therapy in peripheral arterial disease. Consensus statement. 2003 , 26, 1-16	53
2229	Management of secondary risk factors in patients with intermittent claudication. 2003 , 26, 262-6	25
2228	Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents. 2003 , 26, 374-80	19
2227	NSAIDs and aspirin: friends or foes?. 2003 , 70, 89-90	3
2226	Reperfusion in acute myocardial infarction: current concepts. 2003 , 45, 481-92	4
2225	Implementing guidelines in primary care: can population impact measures help?. 2003 , 3, 7	23
2224	Aspirin dosage and thromboxane synthesis in patients with vascular disease. 2003 , 23, 579-84	45
2223	Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. 2003 , 92, 1492-4	114
2222	Prothrombotic and antithrombotic pathways in acute coronary syndromes. 2003 , 91, 3H-11H	320
2221	Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. 2003 , 125, 1481-92	313
2220	Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. 2003 , 18, 425-31	18

2219	AINS et aspirine : Amis ou ennemis ?. 2003 , 70, 7-8	1
2218	Should aspirin be used to counteract 'salicylate deficiency'?. 2003 , 93, 153-5	4
2217	Acute coronary disease Athero-Inflammation: Therapeutic approach. 2003 , 1, 2	7
2216	Impact of smoking reduction on coronary heart disease mortality trends during 1981-2000 in England and Wales. 2003 , 1, 185	6
2215	Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. 2003 , 254, 67-75	103
2214	Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. 2003 , 254, 95-101	41
2213	Applying multiple interventions in chronic kidney disease. 2003 , 16, 157-64	13
2212	Biphasic pro-thrombotic and inflammatory responses after coronary artery bypass surgery. 2003 , 1, 470-6	28
2211	Aspirin resistance: definition, mechanisms and clinical read-outs. 2003 , 1, 1710-3	224
2210	Aspirin resistance: a revival of platelet aggregation tests?. 2003 , 1, 2048-50	50
2209	Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. 2003 , 14, S60-3	27
2208	The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. 2003 , 58, 28-35	84
2207	Stroke, dementia, and drug delivery. 2004 , 57, 15-26	8
2206	A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. 2003 , 12, 669-78	34
2205	Antiplatelet therapy: in search of the 'magic bullet'. 2003 , 2, 775-89	152
2204	COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. 2003 , 2, 879-90	353
2203	Scientific and therapeutic advances in antiplatelet therapy. 2003 , 2, 15-28	288
2202	Mechanisms, challenges and opportunities in stroke. 2003 , 4, 399-415	1363

2201	Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?. 2003 , 29, 769-88	6
2200	[Interaction of angiotensin-converting enzyme inhibitors with aspirin]. 2003 , 121, 631-3	
2199	[Present and future of antithrombotic therapy in acute coronary syndromes]. 2003 , 56, 115-20	
2198	[Review of plasma anti-aggregants and their indications in primary care. Eight years later]. 2003 , 31, 252-63	
2197	Aspirin for the prevention of cardiovascular events in the elderly. 2003 , 20, 999-1010	16
2196	Antiplatelet prescribing patterns for TIA and ischemic stroke: the Indiana University experience. 2003 , 207, 5-10	7
2195	Oral anticoagulants in patients with coronary artery disease. 2003 , 41, 62S-69S	106
2194	Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. 2003 , 41, 79S-88S	70
2193	Aspirin resistance: a new independent predictor of vascular events?. 2003 , 41, 966-8	98
2192	A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. 2003 , 41, 961-5	836
2191	A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. 2003 , 42, 775-80	162
2190	Resistance in vitro to low-dose aspirin is associated with platelet PIA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. 2003 , 42, 1115-9	146
2189	Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. 2003 , 26, 913-24	15
2188	Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. 2003 , 42, 909-20	21
2187	Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. 2003 , 42, 1059-70	54
2186	NCX4016: a novel antithrombotic agent. 2003 , 35 Suppl 2, S20-6	6
2185	'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. 2003 , 32, 1-22	2414
2184	Chronic myeloproliferative disorders. 2003 , 2003, 200-24	78

2183	Role of antiplatelet drugs in the prevention of cardiovascular events. 2003 , 110, 355-9	44
2182	Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. 2003 , 111, 165-70	61
2181	The epidemiological night where all patients are black: will pharmacogenetics shed some light?. 2003 , 112, 273-4	6
2180	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. 2003 , 146, 591-604	100
2179	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. 2003 , 108, 1655-61	342
2178	Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?. 2003 , 4, 11-6	8
2177	Oral anticoagulants in patients with coronary artery disease: an inexpensive and effective strategy. 2003 , 109, 159-61	3
2176	Cooperative effect of GNB3 825C>T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation. 2003 , 109, 279-86	23
2175	Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. 2003 , 110, 281-6	56
2174	Aspirin and stroke prevention. 2003 , 110, 349-53	9
2173	Activation of nuclear receptors by prostaglandins. 2003 , 110, 311-5	46
2172	Parsing an enigma: the pharmacodynamics of aspirin resistance. 2003 , 361, 542-4	62
2171	Acute myocardial infarction. 2003 , 361, 847-58	246
2170	Effect of ibuprofen on cardioprotective effect of aspirin. 2003 , 361, 1559	0
2169	Effect of ibuprofen on cardioprotective effect of aspirin. 2003 , 361, 1560; author reply 1561	1
2168	Effect of ibuprofen on cardioprotective effect of aspirin. 2003 , 361, 1561	0
2167	Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. 2003 , 301, 143-6	13
2166	Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. 2003 , 308, 956-60	126

2165	Ischemic heart disease in type 2 diabetes. 2003 , 52, 6-12	11
2164	Depression and cardiovascular disease: mechanisms of interaction. 2003 , 54, 248-61	354
2163	[Atorvastatin and clopidogrel. A possible drug interaction with clinical consequences still unknown]. 2003 , 24, 498-500	0
2162	Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. 2003 , 362, 789-97	316
2161	Improving antithrombotic treatment in patients after myocardial infarction. 2003 , 362, 757	1
2160	Stroke. 2003 , 362, 1211-24	332
2159	The role of clopidogrel in the management of acute coronary syndromes. 2003 , 25, 2155-81	9
2158	Platelet activation and antiplatelet therapy in patients with ischemic stroke. 2003 , 1251, 57-70	1
2157	A quantitative illustration of the public health potential of aspirin. 2003 , 60, 900-2	6
2156	Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. 2003 , 24, 245-52	99
2155	Utility of platelet adp receptor antagonism in the emergency department: a review. 2003 , 24, 45-54	2
2154	Essential thrombocythemia. 2003 , 17, 1175-90, vii	23
2153	Carotid ultrasound findings as a predictor of long-term survival after abdominal aortic aneurysm repair: a 14-year prospective study. 2003 , 38, 1220-5	19
2152	Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. 2003 , 38, 710-3	94
2151	[Administration-time dependent effects of acetyl-salicylic acid on blood pressure in patients with mild essential hypertension]. 2003 , 120, 686-92	6
2150	Benefits of optimising drug treatment in home-dwelling elderly patients with coronary artery disease. 2003 , 20, 585-95	6
2149	Platelets, atherosclerosis and the endothelium: new therapeutic targets?. 2003 , 12, 1765-76	12
2148	Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. 2003 , 4, 587-90	5

2147	Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. 2003 , 108, 1682-7	578
2146	New antithrombotic drugs on the horizon. 2003 , 12, 781-97	31
2145	Antithrombotic drug treatment of pediatric patients with ischemic stroke. 2003 , 5, 167-75	18
2144	Stable Angina. 2003 , 3, 1-10	7
2143	Preventing macrovascular disease in patients with type 2 diabetes mellitus. 2003 , 3, 283-97	14
2142	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52	10207
2141	High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. 2003 , 26, 3357-8	17
2140	Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. 2003 , 108, 1191-5	214
2139	The platelet in diabetes: focus on prevention of ischemic events. 2003 , 26, 2181-8	252
2138	Early and late effects of clopidogrel in patients with acute coronary syndromes. 2003 , 107, 966-72	250
2137	Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. 2003 , 23, 1345-51	92
2136	Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. 2003 , 107, 1568-9	31
2135	Antiplatelet therapy for acute ischaemic stroke. 2000 , CD000029	40
2134	Transient ischaemic attacks: desired diagnosis and management by Polish primary care physicians. 2003 , 20, 464-8	10
2133	Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. 2003 , 41, 1259-67	56
2132	Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. 2003 , 34, 840-8	113
2131	Prevention of cardiovascular ischemic events: high-risk and secondary prevention. 2003 , 107, 2059-65	40
2130	The case for early detection and integrated intervention in patients with peripheral arterial disease and intermittent claudication. 2003 , 10, 601-13	8

2129	Decisional attributes of patients with diabetes: the aspirin choice. 2003 , 26, 2804-9	9
2128	Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. 2003 , 26, 3264-72	328
2127	Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. 2003 , 107, 2640-5	13
2126	Oral antithrombotic use among myocardial infarction patients. 2003 , 37, 143-6	2
2125	Drug therapy for prevention of recurrent myocardial infarction. 2003 , 37, 1465-77	21
2124	Aspirin for primary prevention of cardiovascular events in diabetes. 2003 , 26, 3349-50	18
2123	Platelets as predictors of vascular risk: is there a practical index of platelet activity?. 2003 , 9, 177-90	198
2122	Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. 2003 , 12, 259-62	8
2121	Consultations on patients with venous or arterial diseases. 2003 , 2003, 540-58	2
2120	Developing pharmaceutical treatments for peripheral artery disease. 2003 , 12, 101-8	5
2119	Update on acute coronary syndromes and implications for therapy. 2003 , 12, 1971-83	3
2118	Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behavior among Italian general practitioners in diabetic patients: an intervention trial. 2003 , 26, 1497-500	76
2117	Aspirin dose for prevention of cardiovascular disease in diabetics. 2003 , 37, 116-21	8
2116	Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. 2003 , 108, 542-7	249
2115	Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. 2003 , 52, 600-8	117
2114	Antiplatelet treatment in stable coronary artery disease. 2003 , 89, 1273-8	6
2113	Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. 2003 , 34, 2072-80	58
2112	Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. 2003 , 290, 86-97	681

2111	Indirect comparison meta-analysis of aspirin therapy after coronary surgery. 2003 , 327, 1309	49
2110	Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. 2003 , 108, III28-37	34
2109	Are patients with acutely recovered cerebral ischemia more unstable?. 2003 , 34, 2446-50	58
2108	Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. 2003 , CD001458	28
2107	A strategy to reduce cardiovascular disease by more than 80%. 2003 , 326, 1419	937
2106	Initiating antiplatelet therapy in diabetes: a PCO view. 2003 , 3, 349-353	0
2105	Aspirin, clopidogrel, or both for secondary prevention of coronary disease. 2003 , 348, 560-3; author reply 560-3	5
2104	Consensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbs. 2003 , 14, 403-6	1
2103	Advances in antiplatelet therapy. 2003 , 8, 349-63	17
2102	Cervical arterial dissection: time for a therapeutic trial?. 2003 , 34, 2856-60	207
2101	Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. 2003 , 34, 2339-42	25
2100	Atheroscleroti carotidea: Medical Therapy and Clinical Trials. 2003 , 16, 27-30	
2099	Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. 2003 , 15, 173-8	51
2098	No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein IIIa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction. 2003 , 14, 749-53	16
2097	Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. 2003 , 43, 983-9	13
2096	Stroke: a vascular pathology with inadequate management. 2003 , 21, S3-7	12
2095	International Society of Hypertension (ISH). 2003 , 21, 651-663	36
2094	Contemporary use of antiplatelet therapies in percutaneous coronary interventions. 2003 , 14, 373-80	2

2093	10 most commonly asked questions about which antiplatelet agent to prescribe. 2003 , 9, 318-22	
2092	Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A. 2003 , 112, 177-85	23
2091	Potential value of triple antiplatelet therapy for secondary stroke prevention. 2003 , 34, e182-3	1
2090	Platelets and anti-platelet therapy. 2003 , 93, 381-96	80
2089	Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs. 2003 , 34, 379-386	78
2088	Antiplatelet and anticoagulation for patients with prosthetic heart valves. 2003 , CD003464	25
2087	Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. 2000 , CD000248	11
2086	Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. 2003 , 67, 697-700	9
2085	Fibrinogen depleting agents for acute ischaemic stroke. 2000 , CD000091	14
2084	Antiplatelet drugs. 1999 , 170, 379-82	44
2083	Antiplatelet agents for intermittent claudication. 2003 ,	6
2082	Triflusal for preventing serious vascular events in people at high risk. 2003 ,	
2081	Aspirin for cardiovascular disease prevention. 2003 , 179, 147-152	37
2080	Recovery of platelet function after withdrawal of cilostazol administered orally for a long period. 2003 , 10, 348-54	12
2079	[Platelet aggregation test: application in the control of antiplatelet aggregation in the secondary prevention of stroke]. 2003 , 61, 764-7	4
2078	Ever decreasing circles: advances in antiplatelet therapy and anticoagulation. 2003 , 34, 348-50	1
2077	Different locations of atherosclerosis--different risk factors, different therapies?. 2003 , 33, 262-6	2
2076	Braving New Worlds: To Conquer, to Endure. 2004 , 84, 1056-1086	8

2075 Arresting cardiovascular disease progression. Early treatment may counteract high risk. **2004**, 116, 45-8

2074 Antiplatelet therapy for secondary prevention of the complications of atherothrombotic disease. **2004**, 19, 813-23

2073 Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. **2004**, 181, 150-4 70

2072 [Clinical aspects of acute coronary syndromes]. **2004**, 20, 402-7 1

2071 Prevention of cardiovascular disease: an evidence-based clinical aid. **2003**, 181, 1-14 4

2070 Prevention of cardiovascular disease: an evidence-based clinical aid 2004. **2004**, 181, S1-S14 6

2069 Aspirin for cardiovascular disease prevention. **2004**, 180, 94-94

2068 Secondary prevention of acute coronary syndromes. **2004**, 44, S28-35; quiz S35-6 3

2067 Medical management of chronic ischemic heart disease. Selecting specific drug therapies, modifying risk factors. **2004**, 115, 39-46 2

2066 Antiplatelet agents in atherothrombotic diseases. **2004**, 65, 72-5

2065 Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin?. **2004**, 35, 2606-8 23

2064 Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. **2004**, 171, 1189-92 116

2063 Dextran 40 reduces in vitro platelet aggregation in peripheral arterial disease. **2004**, 15, 215-22 21

2062 Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. **2004**, 109, 745-9 245

2061 Economic modelling of antiplatelet therapy in the secondary prevention of stroke. **2004**, 7, 117-134 5

2060 The role of aspirin in cardiovascular diseases--forgotten benefits?. **2004**, 5, 109-15 16

2059 Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. **2004**, 5, 493-503 14

2058 Platelet function testing in cardiovascular diseases. **2004**, 110, e489-93 223

2057	Clopidogrel resistance: a new chapter in a fast-moving story. 2004 , 109, 3064-7	155
2056	Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. 2004 , 10, 9-18	12
2055	Adjunctive treatment in patients treated with thrombolytic therapy. 2004 , 90, 581-8	8
2054	Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. 2004 , 109, 3112-21	274
2053	Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 2004 , 109, 1468-71	195
2052	Atherosclerotic Vascular Disease Conference: Writing Group V: medical decision making and therapy. 2004 , 109, 2634-42	42
2051	Statins for stroke prevention: disappointment and hope. 2004 , 109, III44-9	42
2050	Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. 2004 , 109, 3000-6	167
2049	Pulmonary embolism after coronary artery bypass grafting. 2004 , 109, 2712-5	23
2048	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004 , 110, 508-536	1550
2047	Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. 2004 , 110, 1202-8	667
2046	Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. 2004 , 110, 2361-7	272
2045	Management of acute coronary syndromes: an update. 2004 , 90, 698-706	25
2044	The absolute risk of recurrent myocardial infarction is similar amongst both sexes: MONICA Iceland Study 1981-1999. 2004 , 11, 121-4	1
2043	COX-2 and the cardiovascular system. 2004 , 161-178	
2042	Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. 2004 , 24, 1980-7	338
2041	Antiplatelet therapy in cardiovascular disease. 2004 , 80, 155-64	39
2040	New perspectives on the pharmacotherapy of ischemic stroke. 2004 , 44, S46-56; quiz S56-7	9

2039	Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 483S-512S	378
2038	Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 513S-548S	170
2037	Chapter 7 Small-Vessel Occlusive Disease (Lacunar Stroke). 2004 , 29, 123-138	
2036	Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. 2004 , 43, 669-76	26
2035	Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. 2004 , 328, 693-7	42
2034	Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?. 2004 , 35, 389-91	13
2033	Measurement of the antiplatelet effects of aspirin in cerebrovascular disease. 2004 , 35, e146-7; author reply e146-7	2
2032	The Willis Lecture 2003: evaluating treatments for stroke patients too slowly: time to get out of second gear. 2004 , 35, 2211-9	6
2031	The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. 2004 , 22 Suppl 4, 19-27	23
2030	Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 609S-626S	140
2029	Aspirin Resistance in Diabetic Patients: Response to de Gaetano. 2004 , 27, 1246-1246	1
2028	Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. 2004 , 9, 90	1
2027	The Clinical Impact of Administering Warfarin to Post-Myocardial Infarction Patients. 2004 , 17, 266-269	
2026	Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. 2004 , 27, 2752-4	18
2025	The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. 2004 , 15, 439-46	24
2024	Anticoagulants for acute ischaemic stroke. 2004 , CD000024	50
2023	Ticlopidine. 2004 , 2, 163-176	1
2022	Management of the elderly person after myocardial infarction. 2004 , 59, 1173-85	8

2021	Lessons learned from a clinical trial. 2004 , 110, 3610-4	8
2020	Efficacy and safety of low-dose aspirin in polycythemia vera. 2004 , 350, 114-24	744
2019	Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes. 2004 , 17, 347-369	1
2018	Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. 2004 , 58, 346-53	33
2017	Clopidogrel in the management of cerebrovascular events. 2004 , 58, 402-10	3
2016	Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. 2004 , 58, 153-68	3
2015	Changing aspirin use in patients with Type 2 diabetes in the UKPDS. 2004 , 21, 1368-71	34
2014	Platelet activation in type 2 diabetes mellitus. 2004 , 2, 1282-91	322
2013	Aspirin resistance in vitro and hypertension in stroke patients. 2004 , 2, 2051-3	7
2012	A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. 2004 , 2, 1934-40	65
2011	Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?. 2004 , 18, 821-5	13
2010	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. 2004 , 18, 139-85	868
2009	Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. 2004 , 73, 227-42	6
2008	Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. 2004 , 73, 191-213	15
2007	[Epidemiology of digestive complications associated with use of low-dose aspirin]. 2004 , 28 Spec No 3, C37-44	3
2006	Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases. 2004 , 483, 187-94	13
2005	Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. 2004 , 484, 19-27	17
2004	Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. 2004 , 488, 79-83	21

2003	Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. 2004 , 499, 315-24	33
2002	Lipophilicity-related inhibition of blood platelet aggregation by nipecotic acid anilides. 2004 , 22, 153-64	16
2001	Aspirin resistance in cardiovascular disease: a review. 2004 , 27, 456-65	36
2000	Prevalence and risk of thrombophilia defects in vascular patients. 2004 , 28, 124-31	13
1999	Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices. 2004 , 1011, 148-55	11
1998	Epidemiologische aspecten van cerebrovasculaire aandoeningen in Nederlandberoerte. 2004 , 20, 6-12	
1997	Trombocytenaggregatieremming of antistolling?acetylsalicylzuur trombocytenaggregatieremmers antistollingsmiddelen hart- en vaatziekten. 2004 , 20, 40-43	1
1996	Drug treatment of claudication. 2004 , 13, 16-20	
1995	The efficacy and safety of perioperative antiplatelet therapy. 2004 , 17, 21-7	77
1994	Patient-specific antiplatelet therapy. 2004 , 17, 63-77	1
1993	Secondary stroke prevention: review of clinical trials. 2004 , 27, 1125-35	4
1992	Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. 2004 , 117 Suppl 5A, 72S-78S	11
1991	[Secondary prevention of cardiovascular diseases]. 2004 , 45 Suppl 1, S23-30	
1990	[Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke--update 2003. Part 2: prevention and rehabilitation]. 2004 , 75, 380-8	13
1989	Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. 2004 , 47, 1257-1265	89
1988	Biomimetic actuators: where technology and cell biology merge. 2004 , 61, 2497-509	43
1987	Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. 2004 , 61, 1975-84	46
1986	Clopidogrel: how good is it and how does it work?. 2004 , 6, 264-8	13

1985	Do statins prevent heart failure in patients after myocardial infarction?. 2004 , 1, 156-60	1
1984	Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. 2004 , 6, 351-6	11
1983	The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. 2004 , 2, 1	67
1982	Review article: the ageing bowel and intolerance to aspirin. 2004 , 19, 39-45	9
1981	Population-based study of carotid endarterectomy in Western Australia. 2004 , 91, 168-73	5
1980	Antioxidant effect of acetylsalicylic and salicylic acid in rat brain slices subjected to hypoxia. 2004 , 75, 280-90	31
1979	Novel therapies for the prevention of stroke. 2004 , 13, 1615-30	2
1978	Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease. 2004 , 20, 1851-5	4
1977	Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation. 2004 , 13, 457-60	16
1976	Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke. 2004 , 20, 1845-9	3
1975	Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. 2004 , 38, 353-6	53
1974	Secondary prevention of stroke: a practical guide to drug treatment. 2004 , 18, 221-41	10
1973	Weigh risks and benefits of aspirin in the secondary or primary prevention of cardiovascular events in elderly individuals. 2004 , 20, 8-11	
1972	Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. 2004 , 4, 57-67	25
1971	Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. 2004 , 4, 87-106	21
1970	Aspirin in cardiovascular disorders. What is the optimum dose?. 2004 , 4, 151-8	14
1969	[Acetylsalicylic acid consumption in patients with diabetes mellitus]. 2004 , 122, 96-8	6
1968	El sistema hemostático en los síndromes coronarios agudos: implicaciones fisiopatológicas y terapéuticas. 2004 , 204, 221-227	1

1967	Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. 2004 , 57, 963-980	0
1966	[Peripheral arterial disease: what management practices for general practitioners?]. 2004 , 29, 249-56	6
1965	Valoración clínica del empleo preventivo de la antiagregación plaquetaria. 2004 , 204, 106-108	
1964	Ischemic heart disease and congestive heart failure in diabetic patients. 2004 , 88, 1037-61, xi-xii	18
1963	Coronary artery disease and prevention of heart failure. 2004 , 88, 1209-35	17
1962	Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?. 2004 , 40, 691-7	42
1961	[Anti-platelet agents in neurological practice]. 2004 , 160, 131-6	
1960	[Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?]. 2004 , 34, 374-8	0
1959	Medical treatment of peripheral arterial disease: a comprehensive review. 2004 , 15, 1197-207	69
1958	Peripheral arterial disease in the catheterization laboratory: an underdetected and undertreated risk factor. 2004 , 79, 1107-9	3
1957	[Primary prevention of acute myocardial infarction with aspirin]. 2004 , 122, 592-4	1
1956	Management of metabolic syndrome: aspirin. 2004 , 33, 577-93, vii	17
1955	[Aspirin use in patients with diabetes mellitus]. 2004 , 123, 237-8; author reply 239	
1954	Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. 2004 , 127, 395-402	145
1953	Aspirin in the XXI century: its major clinical impact, novel mechanisms of action, and new safer formulations. 2004 , 127, 341-3	14
1952	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. 2004 , 43, 979-84	113
1951	The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. 2004 , 43, 985-90	102
1950	Aspirin dose and six-month outcome after an acute coronary syndrome. 2004 , 43, 972-8	42

1949	Reply. 2004 , 43, 1135	1
1948	Aspirin resistance: more than just a laboratory curiosity. 2004 , 43, 1127-9	90
1947	Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. 2004 , 43, 2000-8	41
1946	The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. 2004 , 44, 1587-92	269
1945	Foundation and sites of action of antithrombotic agents. 2004 , 17, 3-22	7
1944	The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 2004 , 10, 101-12	82
1943	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. 2004 , 15, 117-25	61
1942	Platelet glycoprotein Ia C807T, Ib C3550T, and IIIa Pl(A1/A2) polymorphisms and ischemic stroke in young Taiwanese. 2004 , 227, 1-5	22
1941	Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. 2004 , 64, 2315-43; discussion 2344-5	56
1940	Risk reduction strategies in ischaemic stroke : the role of antiplatelet therapy. 2004 , 24, 245-54	13
1939	Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. 2004 , 35, 2477-83	102
1938	Cronobiología y cronoterapia en la hipertensión arterial: implicaciones diagnósticas, pronósticas y terapéuticas. 2004 , 21, 256-270	
1937	Lifelong aspirin supplementation as a means to extending life span. 2004 , 7, 243-51	23
1936	[Underutilization of acetylsalicylic acid of cardiovascular prevention in patients with diabetes mellitus]. 2004 , 122, 101-3	1
1935	Review finds further work is required to define and assess the incidence of aspirin resistance. 2004 , 8, 267; discussion 268-9	
1934	Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. 2004 , 113, 101-13	143
1933	Aspirin resistance and diabetic angiopathy: back to the future. 2004 , 113, 97-9	18
1932	Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 , 114, 235-43	22

1931 [Is aspirin resistance a reality?]. **2004**, 25, 101-3

1930 [Retinal vascular occlusions: diagnosis and management]. **2004**, 25, 881-90

1

1929 Antioxidant effects of a single dose of acetylsalicylic acid and salicylic acid in rat brain slices subjected to oxygen-glucose deprivation in relation with its antiplatelet effect. **2004**, 358, 153-6

26

1928 Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention. **2004**, 13, 196-207

18

1927 Sub-optimal taurine status may promote platelet hyperaggregability in vegetarians. **2004**, 63, 426-33

22

1926 Does stenting save lives? Understanding the strengths and limitations of meta-analysis. **2004**, 147, 756-8

3

1925 The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. **2004**, 148, 157-64

309

1924 Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. **2004**, 148, 263-8

171

1923 How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. **2004**, 148, 1028-33

16

1922 Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. **2004**, 116, 119-29

3

1921 Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. **2004**, 116 Suppl 5A, 47S-63S

25

1920 Clinical significance of PLA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support. **2004**, 77, 869-74; discussion 874

30

1919 Should hypertensive patients take aspirin? A report from the Food and Drug Administration. **2004**, 6, 146-9

2

1918 Hypertension and end-organ disease in African Americans: case presentations. **2004**, 6, 48-53

1

1917 Improving outcomes in the post-myocardial infarction setting. **2004**, 6, 34-41

3

1916 [Treatment of carotid stenosis: angioplasty, a well thought-out choice]. **2004**, 33, 1099-102

0

1915 Atherothrombosis: the role of tissue factor. **2004**, 36, 25-30

19

1914 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). **2004**, 11, 671-718

940

1913	First-generation agents: aspirin, heparin and coumarins. 2004 , 17, 23-53	22
1912	Stroke and neurodegenerative disorders. 1. Acute stroke evaluation, management, risks, prevention, and prognosis. 2004 , 85, S3-10	38
1911	Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative. 2004 , 41, 35-41	24
1910	Pulmonary embolism. 2004 , 363, 1295-305	305
1909	Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). 2004 , 363, 1925-33	722
1908	Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. 2004 , 364, 331-7	1728
1907	Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. 2004 , 26, 439-46	18
1906	Acute Ischaemic Stroke: Management, Recent Advances and Controversies. 2004 , 11, 35-52	
1905	Long-term management of atherothrombosis. 2004 , 65, 206-9	3
1904	Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. 2004 , 77, 1848-53	48
1903	Current and future concepts in stroke prevention. 2004 , 170, 1123-33	19
1902	Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. 2004 , 44, 777-84	29
1901	Antiplatelet effect of aspirin in patients with cerebrovascular disease. 2004 , 35, 175-8	157
1900	Stroke care delivery in institutions participating in the Registry of the Canadian Stroke Network. 2004 , 35, 1756-62	92
1899	Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 549S-575S	72
1898	Peripheral Arterial Disease. 2004 , 46, 9-12	
1897	In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. 2004 , 43, 74-82	28
1896	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004 , 126, 234S-264S	494

1895	Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors. 2004 , 43, 423-31	9
1894	Acetylsalicylic acid inhibits monocyte adhesion to endothelial cells by an antioxidative mechanism. 2004 , 43, 514-21	17
1893	Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. 2004 , 31, 295-303	1
1892	Peripheral Arterial Disease in the Catheterization Laboratory: An Underdetected and Undertreated Risk Factor. 2004 , 79, 1107-1109	10
1891	Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. 2004 , 15, 129-30	2
1890	The Top 12 Advances in Vascular Medicine. 2004 , 11, II-21-II-31	1
1889	Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. 2004 , 15, 295-301	52
1888	Chronotherapy of hypertension. 2004 , 13, 501-5	64
1887	Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. 2004 , 59, 329-39	3
1886	Aspirin resistance. 2004 , 328, 477-9	80
1885	Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy. 2004 , 44, S37-44; quiz S44-5	25
1884	ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?. 2004 , 116, 11-6, 19-22, 48	8
1883	Atherothrombosis: epidemiology, pathophysiology, and prevention. 2004 , 44, S5-12; quiz S12-3	48
1882	Current Topics on Cerebrovascular Disease. 2004 , 19, 27-30	
1881	Prévention des accidents vasculaires cérébraux. 2004 , 1, 1-20	1
1880	Anti-inflammatory and antipyretic analgesics and drugs used in gout. 2004 , 27, 102-117	
1879	Chapter 9 Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke. 2004 , 29, 175-196	
1878	Emerging therapies: clopidogrel and aspirin. 2005 , 36, 707	3

1877	Antithrombotic properties of the thromboxane A ₂ /prostaglandin H ₂ receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. 2005 , 45, 389-95	11
1876	The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. 2005 , 16, 337-40	4
1875	Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. 2005 , 13, 108-10	18
1874	Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. 2005 , 50, 69-72	1
1873	Stroke prevention. MATCHing therapy to the patient with TIA. 2005 , 117, 26-30	5
1872	Management of peripheral arterial disease. 2005 , 13, 61-8	54
1871	The clinical epidemiology of cardiovascular disease in chronic kidney disease. 2005 , 14, 550-7	24
1870	The significance of prestroke aspirin dosage in fatal outcome of acute stroke. 2005 , 28, 55-9	4
1869	Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. 2005 , 330, 1306	36
1868	[Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events?]. 2005 , 60, 137-47	2
1867	Anticoagulation and platelet antiaggregation therapy in stroke prevention. 2005 , 4, 127-131	
1866	Anticoagulation and platelet antiaggregation therapy in stroke prevention. 2005 , 18, 53-7	2
1865	Using aspirin to prevent stroke. 2005 , 18, 55	
1864	Clopidogrel and aspirin versus aspirin for preventing cardiovascular disease in those at high risk. 2005 ,	
1863	Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A. 2005 , 106, 913-21	47
1862	Impact of smoking status on long-term mortality in patients with acute myocardial infarction. 2005 , 69, 7-12	41
1861	2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Part 5: Acute coronary syndromes. 2005 , 67, 249-69	34
1860	Variability in response to aspirin: do we understand the clinical relevance?. 2005 , 3, 665-9	51

1859	SHPS-1 negatively regulates integrin alphaIIb beta3 function through CD47 without disturbing FAK phosphorylation. 2005 , 3, 763-74	19
1858	Medical management of peripheral arterial disease. 2005 , 3, 1628-37	43
1857	Aspirin resistance. 2005 , 3, 1655-62	61
1856	Therapeutic approaches in arterial thrombosis. 2005 , 3, 1577-89	63
1855	Preventable stroke and stroke prevention. 2005 , 3, 1638-45	36
1854	Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No. 2005 , 3, 1137-40	2
1853	Prevention of venous thromboembolism after acute ischemic stroke. 2005 , 3, 1187-94	70
1852	Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: Yes. 2005 , 3, 1133-6	1
1851	The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. 2005 , 3, 1437-45	56
1850	Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. 2005 , 3, 2315-23	55
1849	Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. 2005 , 3, 2245-53	15
1848	Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. 2005 , 3, 2784-9	60
1847	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. 2005 , 3, 2649-55	45
1846	Is aspirin effective in diabetic patients? No. 2005 , 3, 2615-6	8
1845	Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. 2005 , 68, 1419-26	9
1844	Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. 2005 , S44-7	70
1843	Atherothrombosis: management of patients at risk. 2005 , 59, 407-14	4
1842	Antithrombotic therapy for congestive heart failure. 2006 , 60, 36-47	9

1841	FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban. 2005 , 25, 75-86	11
1840	Aspirin and endothelial function in hypertension. 2005 , 19, 663-5	8
1839	Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. 2005 , 19, 667-73	40
1838	Review article: a cardiologist's view of the risks and benefits of cyclo-oxygenase-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs. 2005 , 1, 11-15	0
1837	2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets. 2005 , 527, 37-43	21
1836	Life-style modification in peripheral arterial disease. 2005 , 29, 2-9	27
1835	Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. 2005 , 29, 171-6	68
1834	Emboli rate during and early after carotid endarterectomy after a single preoperative dose of 120 mg acetylsalicylic acid--a prospective double-blind placebo controlled randomised trial. 2005 , 29, 156-61	10
1833	Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. 2005 , 29, 190-8	20
1832	Antithrombotic strategies in vascular surgery: evidence and practice. 2005 , 29, 516-21	13
1831	Comprehensive endovascular therapy for femoropopliteal arterial atherosclerotic occlusive disease. 2005 , 201, 275-96	32
1830	Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. 2005 , 95, 1218-22	267
1829	Can the time of taking aspirin influence the frequency of cardiovascular events?. 2005 , 96, 608-10	11
1828	[Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey]. 2005 , 54, 184-9	1
1827	Estrategia invasiva contemporánea en los pacientes con síndrome coronario agudo sin elevación del segmento ST. 2005 , 5, 26C-39C	
1826	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. 2005 , 45, 473-84	152
1825	Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?. 2005 , 45, 607-9	1
1824	Antiplatelet drug resistance: not ready for prime time. 2005 , 25, 1621-8	5

1823	Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. 2005 , 25, 847-61	4
1822	Aspirin resistance: an evaluation of current evidence and measurement methods. 2005 , 25, 942-53	26
1821	Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. 2005 , 92, 159-65	50
1820	Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. 2005 , 61, 595-601	10
1819	[Acute coronary syndrome in the prehospital phase]. 2005 , 54, 957-74	2
1818	[Preoperative long-term therapy]. 2005 , 54, 902-13	4
1817	[Haemostaseology]. 2005 , 46, 873-8, 880-1	
1816	[Anticoagulation for secondary prevention: which drug in which situation?]. 2005 , 46, 1310-7	
1815	Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids. 2005 , 371, 81-8	5
1814	Current treatments in neurology: stroke. 2005 , 252, 260-7	7
1813	Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic procedures. 2005 , 40, 698-707	35
1812	Platelets and atherothrombosis: An essential role for inflammation in vascular disease [A review. 2005 , 14, 211-217	2
1811	Aspirin and clopidogrel: Efficacy, treatment, and resistance in coronary artery disease. 2005 , 14, 109-114	
1810	Novel serologic markers of cardiovascular risk. 2005 , 7, 148-54	9
1809	Evidence-based management of peripheral vascular disease. 2005 , 7, 358-63	17
1808	Issues with care in the elderly patient presenting with acute ischemia. 2005 , 7, 270-5	0
1807	Transient ischemic attack: a neurologic emergency. 2005 , 5, 13-20	12
1806	Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patients. 2005 , 50, 1621-4	11

1805	The HOPE TIPS: the HOPE study translated into practices. 2005 , 19, 197-201	12
1804	Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel. 2005 , 19, 291-9	1
1803	Multidisciplinary vascular screening program modestly improves the medical treatment of vascular risk factors. 2005 , 19, 429-35	7
1802	Use of antiplatelet drugs in the stroke unit of a Hong Kong hospital. 2005 , 27, 258-62	5
1801	The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. 2005 , 6, 15	28
1800	Prevalence of antiplatelet therapy in patients with diabetes. 2005 , 4, 18	12
1799	Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. 2005 , 3, 10	66
1798	Strokes and diabetes. 2005 , 22, 215-221	2
1797	The withdrawal of rofecoxib. 2005 , 14, 213-7	17
1796	Potential limitations of electronic database studies of prescription non-aspirin non-steroidal anti-inflammatory drugs (NANSAs) and risk of myocardial infarction (MI). 2005 , 14, 513-22	14
1795	The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. 2005 , 18, 331-6	7
1794	Cardiac disease in the non-cardiac surgical population: effect on survival. 2005 , 14, 718-24	1
1793	Diagnosis and prevention of atherosclerotic cerebral infarction. 2005 , 10, 553-64	9
1792	ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events. 2005 , 62, 1398-405	5
1791	Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin. 2005 , 39, 1073-9	13
1790	Risk of hemorrhagic stroke with aspirin use: an update. 2005 , 36, 1801-7	129
1789	Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. 2005 , 59, 1041-6	9
1788	Risk modification in patients with peripheral arterial disease: a retrospective survey. 2005 , 56, 279-87	33

1787	Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. 2005 , 39, 294-300	9
1786	Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. 2005 , 2, e353	46
1785	Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives. 2005 , 46, 1060-8	50
1784	The break-even point: when medical advances are less important than improving the fidelity with which they are delivered. 2005 , 3, 545-52	147
1783	Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. 2005 , 91, 451-5	12
1782	Antiplatelet therapy and prevention of ischaemic events: CAPRIE. 2005 , 5, 203-206	1
1781	Part 8: Stabilization of the Patient With Acute Coronary Syndromes. 2005 , 112, IV-89-IV-110	6
1780	Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. 2005 , 111, 940-53	187
1779	Coronary artery disease in patients with systemic lupus erythematosus. 2005 , 1, 55-9; quiz 60	9
1778	The cardiovascular pharmacology of COX-2 inhibition. 2005 , 2005, 445-51	28
1777	Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. 2005 , 26, 1557-61	88
1776	Unmet medical needs and therapeutic opportunities in stable angina. 2005 , 7, H7-H15	3
1775	Clopidogrel versus aspirin and esomeprazole to prevent recurrent bleeding. 2005 , 352, 1716-8; author reply 1716-8	4
1774	Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. 2005 , 173, 779-88	168
1773	What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?. 2005 , 173, 1024-6	6
1772	Cardiovascular risk in patients with type 2 diabetes. 2005 , 172, 1160	
1771	Management of polycythemia vera and essential thrombocythemia. 2005 , 2005, 201-8	35
1770	Management of patients with type 2 diabetes after acute coronary syndromes. 2005 , 2, 144-54	5

1769	Antiplatelet therapy in ischemic stroke. 2005 , 5, 541-9	1
1768	Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure. 2005 , 5, 277-86	
1767	Inhibition of platelet activation and aggregation. 2005 , 443-62	9
1766	Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. 2005 , 6, 35-43	13
1765	The mechanism of action of omega-3 fatty acids in secondary prevention post-myocardial infarction. 2005 , 21, 95-100	26
1764	Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970-2000. 2006 , 92, 453-60	102
1763	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. 2005 , 26, 1115-40	1642
1762	Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. 2005 , 25, 252-7	107
1761	Contemporary management of acute coronary syndrome. 2005 , 81, 217-22	2
1760	Temporal trends in the incidence of intermittent claudication from 1950 to 1999. 2005 , 162, 430-7	38
1759	Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. 2005 , 112, 1024-9	59
1758	Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. 2005 , 111, 2233-40	597
1757	Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient. 2005 , 6, 2181-92	2
1756	Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives. 2005 , 20 Suppl 2, 109-18	9
1755	Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor. 2005 , 11, 271-7	3
1754	Pathobiology and cell interactions of platelets in diabetes. 2005 , 2, 16-23	48
1753	Controversies in antiplatelet therapy for patients with cardiovascular disease. 2005 , 111, e267-71	16
1752	Should aspirin be discontinued before coronary artery bypass surgery?. 2005 , 112, e85-90	11

1751	Resistance to antiplatelet drugs: current status and future research. 2005 , 6, 2027-45	54
1750	Initial Appraisal of Acute Coronary Syndromes. 2005 , 18, 377-393	
1749	Prevention of venous thromboembolism among hospitalized medical patients. 2005 , 111, e1-3	38
1748	Antiplatelet treatment for coronary heart disease. 2007 , 93, 258-65	29
1747	Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. 2005 , 26, 804-47	1159
1746	Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. 2005 , 111, 334-42	171
1745	Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?. 2005 , 81, 401-3	12
1744	Platelet function testing in cardiovascular diseases. 2005 , 10 Suppl 1, 132-7	7
1743	Antiplatelet and anticoagulant medication usage during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). 2005 , 12, 11-9	49
1742	Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. 2005 , 330, 821	65
1741	Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. 2005 , 36, 162-8	113
1740	Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. 2005 , 36, 276-80	121
1739	Secondary prevention of recurrent stroke. 2005 , 36, 218-21	37
1738	Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. 2005 , 36, 1001-5	145
1737	Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. 2005 , 36, 1597-616	468
1736	Antiplatelet agents in secondary prevention of stroke: a perspective. 2005 , 36, 2034-6	7
1735	Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. 2005 , 26, 1585-95	171
1734	Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit?. 2005 , 365, 341-6	122

1733	The lady aspirin for cardiovascular disease. 2005 , 366, 1148-50	9
1732	Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 2005 , 366, 1607-21	1518
1731	The brain of the elderly diabetic patient. 2005 , 31 Spec No 2, 5S92-5S97	15
1730	[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes]. 2005 , 34, 1295-8	
1729	Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. 2005 , 6, 13-9	27
1728	Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. 2005 , 46, 975-83	65
1727	The metabolic syndrome, hyperlipidemia, and insulin resistance. 2005 , 7, 61-72	54
1726	Enfermedad cerebrovascular (II): tratamiento, prevención secundaria y rehabilitación. 2005 , 12, 11-27	
1725	Antiplatelet therapy in neuroendovascular therapeutics. 2005 , 16, 517-40, vi	32
1724	[Antithrombotic drugs in the prevention of ischemic stroke]. 2005 , 30, 267-79	
1723	Management of peripheral arterial disease in chronic kidney disease. 2005 , 23, 225-36	34
1722	Acute coronary syndromes: risk stratification and initial management. 2005 , 23, 401-9, v	11
1721	Cardiovascular risk prevention in peripheral artery disease. 2005 , 41, 1070-3	18
1720	Management of coronary heart disease: stable angina, acute coronary syndrome, myocardial infarction. 2005 , 32, 1057-81	4
1719	[Discharge prescription for ischemic stroke patients]. 2005 , 161, 738-44	
1718	Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. 2005 , 89, 511-23	9
1717	The evolving role of advanced MR imaging as a management tool for adult ischemic stroke: a Western-European perspective. 2005 , 15, 245-58, ix	20
1716	[Aspirin and temporal arteritis]. 2005 , 30, 5-7	0

1715	Die Kosteneffektivität von Clopidogrel bei Patienten mit Atherosklerose-assoziierten Erkrankungen. 2005 , 3, 9-24	
1714	Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?. 2005 , 39, 135-6	2
1713	Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. 2005 , 21, 101-12	30
1712	Oral antiplatelet therapy and percutaneous coronary intervention. 2005 , 6, 3-12	3
1711	The safety of lumiracoxib when used in the treatment of arthritis. 2005 , 6, 347-50	7
1710	Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) in collaboration with the American Association of	706
1709	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. 2005 , 5, 751-61	3
1708	Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. 2005 , 21, 19-26	53
1707	Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. 2005 , 23, 733-42	18
1706	Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?. 2005 , 5, 307-18	10
1705	Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. 2005 , 6, 359-67	5
1704	Low-dose aspirin for the prevention of atherothrombosis. 2005 , 353, 2373-83	870
1703	Recommendations for the management of patients after heart valve surgery. 2005 , 26, 2463-71	260
1702	Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. 2005 , 9, R636-44	60
1701	Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. 2005 , 352, 1081-91	894
1700	Triflusal for preventing serious vascular events in people at high risk. 2005 , CD004296	32
1699	Stroke in patients with diabetes and hypertension. 2005 , 7, 286-92; quiz 293-4	22
1698	Prevalence of aspirin resistance measured by PFA-100. 2005 , 101, 71-6	47

1697	Antithrombotic strategies for the management of non-valvular atrial fibrillation. 2005 , 100, 191-8	6
1696	Compression stockings and the prevention of symptomatic venous thromboembolism: data from the Tinzaparin in Acute Ischemic Stroke Trial. 2005 , 14, 203-9	7
1695	Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. 2005 , 27, 1806-14	15
1694	Are evidence-based cardiovascular prevention therapies being used? A review of aspirin and statin therapies. 2005 , 1, 285-295	
1693	Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. 2005 , 116, 293-300	7
1692	Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. 2005 , 116, 465-70	29
1691	Marked increase of fibrin gel permeability with very low dose ASA treatment. 2005 , 116, 509-17	35
1690	Effects of dietary supplements on aspirin and other antiplatelet agents: an evidence-based approach. 2005 , 117, 87-101; discussion 113-5	2
1689	Developmental origins of aging in brain and blood vessels: an overview. 2005 , 26, 281-91	58
1688	Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. 2005 , 15, 42-6	7
1687	A health impact assessment of increased aspirin use in Wales. 2005 , 119, 734-7	5
1686	[Pharmacogenetics and antiplatelet drugs]. 2005 , 26, 725-32	1
1685	Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. 2005 , 80, 768-79	54
1684	The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). 2005 , 79, 1454-61	119
1683	Development of a multicenter peripheral arterial interventional database: the PVD-QI2. 2005 , 149, 1003-8	27
1682	Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. 2005 , 149, S19-31	24
1681	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. 2005 , 149, 227-33	43
1680	Management of risk in peripheral artery disease: recent therapeutic advances. 2005 , 150, 35-40	21

1679	Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. 2005 , 150, 1147-53	41
1678	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. 2005 , 150, 401	27
1677	Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. 2005 , 118, 113-22	1
1676	Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. 2005 , 118, 723-7	150
1675	[Which is the limit of the provision of services close to patients? The limit is marked by the tension between "the boatman syndrome" and "the cat syndrome"]. 2005 , 124, 778-81	1
1674	[Guidelines for percutaneous coronary interventions]. 2005 , 58, 679-728	19
1673	[Pharmacological strategies in prevention of vascular injury]. 2005 , 205, 395-7	
1672	[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. 2005 , 58, 1062-92	57
1671	[Aspirin resistance]. 2005 , 124, 30-6	
1670	Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. 2005 , 65, 433-45	7
1669	Aspirin resistance and atherothrombotic disease. 2005 , 46, 986-93	151
1668	Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. 2005 , 45, 177-84	45
1667	Aspirin use in chronic heart failure: what should we recommend to the practitioner?. 2005 , 46, 963-6	20
1666	Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. 2005 , 45, 456-9	305
1665	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. 2005 , 45, 1295-301	225
1664	Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction. 2005 , 46, 967-74	20
1663	Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. 2005 , 46, 1258-63	167
1662	Inhibiteurs du fonctionnement plaquettaire. 2005 , 2, 35-51	

1661	Aspirin resistance in stroke: 2004. 2005 , 229-230, 163-9	30
1660	Seeing the Brain So We Can Save It: The Evolution of Magnetic Resonance Imaging as a Clinical Tool. 2005 , 3-19	
1659	Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. 2005 , CD001925	34
1658	Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. 2005 , 23, 193-210	8
1657	Prevention of cardiovascular events in elderly people. 2005 , 22, 859-76	56
1656	Effect of age-related changes in gastric physiology on tolerability of medications for older people. 2005 , 22, 655-61	16
1655	Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries?. 2005 , 35, 271-83	32
1654	Impact of Coaching Patients on Coronary Risk Factors. 2005 , 13, 225-244	12
1653	A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. 2005 , 352, 1293-304	1488
1652	Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus : management strategies. 2005 , 4, 75-86	8
1651	Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. 2005 , 7 Suppl 4, S14-22	52
1650	Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrhological variables. 2006 , 23, 559-67	30
1649	Drug treatment of peripheral arterial disease in the elderly. 2006 , 23, 1-12	9
1648	Chronic antithrombotic therapy in post-myocardial infarction patients. 2006 , 22, 167-82, x	
1647	Clopidogrel use in coronary artery disease. 2006 , 4, 7-15	4
1646	Optimal medical management of peripheral arterial disease. 2006 , 40, 312-27	52
1645	Bayesian methods for evidence synthesis in cost-effectiveness analysis. 2006 , 24, 1-19	296
1644	Aggressive risk factor modification and pharmacological therapy are the basic steps in managing peripheral arterial disease. 2006 , 22, 17-20	

1643	The role of oral antiplatelet agents in atherothrombotic disease. 2006 , 6, 149-57	15
1642	Role of abciximab in the treatment of coronary artery disease. 2006 , 6, 935-42	10
1641	The Role of Cardiac Rehabilitation in the Treatment and Secondary Prevention of Cardiovascular Disease. 2006 , 13, 21-27	1
1640	Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. 2006 , 17, 100-4	42
1639	Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers. 2006 , 17, 105-7	7
1638	Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems. 2006 , 38, 162-72	37
1637	Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. 2006 , 37, 577-617	1174
1636	Atrial fibrillation and stroke prevention. 2006 , 6, 1523-30	3
1635	Pro: Should aspirin be continued after cardiac surgery in the setting of thrombocytopenia?. 2006 , 20, 112-3	8
1634	Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. 2006 , 9, 56-63	6
1633	Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions?. 2006 , 32, 559-67	8
1632	[Medical management of patients with stable coronary artery disease in France in 2004. Data from the Mutualit�'Sociale Agricole]. 2006 , 35, 1123-30	2
1631	Cardioprotective medication use in hemodialysis patients. 2006 , 22, 755-60	36
1630	Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry. 2006 , 22, 841-7	18
1629	Tratamiento preventivo del ictus. 2006 , 18, 20-33	
1628	Controversia terap�'utica: clopidogrel y estatinas. 2006 , 18, 34-48	
1627	Aspirin resistance. 2006 , 367, 606-17	433
1626	Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. 2006 , 367, 1665-73	792

1625	Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. 2006 , 368, 29-36	486
1624	ESPRIT trial. 2006 , 368, 448-9; author reply 449	5
1623	Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. 2006 , 114, 774-82	1020
1622	Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. 2006 , 46, 981-90	133
1621	Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. 2006 , 184, 8-14	25
1620	Intermittent claudication: an overview. 2006 , 187, 221-37	81
1619	Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. 2006 , 43, 525-32	47
1618	Meeting AHA/ACC secondary prevention goals in a vascular surgery practice: an opportunity we cannot afford to miss. 2006 , 43, 781-7	23
1617	Hipertensi�n Arterial y Cronoterapia. 2006 , 103, 19-29	2
1616	[Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors]. 2006 , 31, 4-9	3
1615	Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. 2006 , 81, 641-52	35
1614	The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. 2006 , 20, 797-809	8
1613	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. 2006 , 354, 1464-76	922
1612	Aspirin and clopidogrel resistance. 2006 , 81, 989; author reply 990	1
1611	Aspirin and clopidogrel resistance. 2006 , 81, 518-26	77
1610	Les antithrombotiques dans la pr�vention des accidents isch�miques c�r�braux. 2006 , 26, 67-77	
1609	Minimally invasive approaches to vascular procedures in the elderly. 2006 , 22, 575-84	2
1608	Update on anticoagulant medications for the interventional radiologist. 2006 , 17, 597-612	14

1607	[Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role?]. 2006 , 31, 129-34	5
1606	[Consultation after cerebral infarction or intracerebral hematoma]. 2006 , 35, 97-104	
1605	Antithrombotic therapy in peripheral arterial disease. 2006 , 22, 183-98, x	1
1604	Clopidogrel desensitization. 2006 , 96, 756-7	15
1603	Antiplatelet agents and arterial thrombosis. 2006 , 22, 57-74, viii	3
1602	Platelets in atherothrombosis. 2006 , 81, 59-68	92
1601	Coronary artery disease screening, treatment, and follow-up. 2006 , 33, 863-85, vi	2
1600	Effect of Combined Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment on 1-Year Survival After Acute Myocardial Infarction: Findings of the PRIAMHO-II Registry. 2006 , 59, 313-320	1
1599	Morbimortalidad por cardiopatía isquémica en el paciente diabético. 2006 , 53, 405-417	1
1598	[Gastric protection and treatment with low-dose aspirin]. 2006 , 126, 232-3	
1597	[Under-use of platelet antiaggregants in patients with cardiovascular disease]. 2006 , 37, 301-2	0
1596	Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II. 2006 , 59, 313-320	15
1595	[Prevention of atherothrombotic disease with the combination of two antiplatelet drugs]. 2006 , 127, 153-5	
1594	[Guidelines on the management of stable angina pectoris. Executive summary]. 2006 , 59, 919-70	22
1593	Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. 2006 , 4, 1337-45	72
1592	Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. 2006 , 17, 218-26	42
1591	Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. 2006 , 17, 209-17	86
1590	Pharmacologic support of the failing heart. 2006 , 86, 1503-21	4

1589	Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?. 2006 , 3, 245-61	21
1588	Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. 2006 , 47, 1182-7	126
1587	ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for	831
1586	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary	372
1585	ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular	184
1584	Secondary stroke prevention and antiplatelet therapy. 2006 , 47, 2568; author reply 2569-70	
1583	Using measures of disease progression to determine therapeutic effect: a sirens' song. 2006 , 48, 434-7	18
1582	Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. 2006 , 48, 438-45	547
1581	Essential thrombocythaemia. 2006 , 19, 439-53	12
1580	Evaluation and therapy for heart failure in the setting of ischemic heart disease. 2006 , 12, e104-11	
1579	Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. 2006 , 55, 67-71	14
1578	Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. 2006 , 11, 170-6	32
1577	Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. 2006 , 5, 83-94	24
1576	Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. 2006 , 6, 87-101	50
1575	Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. 2006 , 152, 967-73	138
1574	Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. 2006 , 30, 74-7	143
1573	Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. 2006 , 119, 624-38	326
1572	Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?. 2006 , 119, 707.e11-6	16

1571	Aspirin to prevent heart attack and stroke: what's the right dose?. 2006 , 119, 198-202	63
1570	Peripheral arterial disease: a review of disease awareness and management. 2006 , 4, 365-79	25
1569	The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. 2006 , 151, 1-9	144
1568	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 2006 , 152, 500-8	7
1567	Aspirin "resistance". 2006 , 36, 171-6	12
1566	Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. 2006 , 17, 349-54	29
1565	The evidence for medicine versus surgery for carotid stenosis. 2006 , 60, 3-7	21
1564	Pharmacotherapy for patients undergoing carotid stenting. 2006 , 60, 14-9	6
1563	The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. 2006 , 37, 1572-7	57
1562	CHARISMA and TROPHY. 2006 , 9, 235-8	1
1561	Building on the specialist's antihypertensive treatment recommendation: it's just the beginning. 2006 , 8, 31-9	1
1560	Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy. 2006 , 15, 250-9	7
1559	Antioxidant and antiplatelet effects of the alpha-tocopherol-aspirin combination in type 1-like diabetic rats. 2006 , 79, 1405-12	10
1558	Effects of aspirin plus alpha-tocopherol on brain slices damage after hypoxia-reoxygenation in rats with type 1-like diabetes mellitus. 2006 , 400, 252-7	8
1557	A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. 2006 , 109, 307-16	20
1556	Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. 2006 , 118, 433-8	11
1555	Anticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter, why not?. 2006 , 118, 429-32	5
1554	Aspirin overprescription in primary cardiovascular prevention. 2006 , 118, 471-7	16

1553	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. 2006 , 113,	347
1552	Aspirin for the Prevention of Cardiovascular Events. 2006 , 49, 181	1
1551	[Targets of antithrombotic drugs]. 2006 , 22, 887-94	1
1550	Medical treatment for carotid stenosis. 59-71	
1549	Guidelines for the management of acute coronary syndromes 2006. 2006 , 184, S1-S32	110
1548	Aspirin for primary prevention of cardiovascular disease in women: does sex matter?. 2006 , 184, 260-1	8
1547	Antiplatelet therapy in the treatment and prevention of thrombus formation. 2006 , 1, 568-574	
1546	Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. 2006 , 70, 453-8	17
1545	[Issues involved with supply of medical and hygienic materials to home care patients]. 2006 , 33 Suppl 2, 273-5	
1544	Is low-dose aspirin a safe and effective option for primary stroke prevention in patients with atrial fibrillation?. 2006 , 3, 248-249	
1543	Antithrombotic therapy in secondary stroke prevention. 2006 , 2, 787-797	
1542	[Antithrombotic drugs and stroke: clinical trials and unanswered questions]. 2006 , 61, 401-5	
1541	Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. 2006 , CD001820	16
1540	Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. 2006 , 42, 81-110	7
1539	Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. 2006 , 37, 134-8	22
1538	The influence of new antithrombotic drugs on regional anesthesia. 2006 , 19, 545-50	34
1537	Thrombolysis for ST-elevation myocardial infarction in the emergency department. 2006 , 5, 141-6	1
1536	Peripheral arterial disease in older adults: management of cardiovascular disease risk factors. 2006 , 21, S15-20	4

1535	Update on clopidogrel and dual anti-platelet therapy: neurology. 2006 , 8, G15-G19	2
1534	Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. 2006 , 48, 1-5	75
1533	Comments and Discussion on the Cocoa-platelet Presentation. 2006 , 47, S206-S209	17
1532	Accidents vasculaires c�r�braux chez la femme. 2006 , 3, 1-14	
1531	Causes cardiaques d'embolie c�r�brale. 2006 , 3, 1-23	
1530	The PGH-synthase system and isozyme-selective inhibition. 2006 , 47 Suppl 1, S1-6	20
1529	Inhibiteurs du fonctionnement plaquettaire. 2006 , 1, 1-12	
1528	Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. 2006 , 7, 608-13	24
1527	CHARISMA: the antiplatelet saga continues. 2006 , 37, 2428-9	6
1526	Aspirin resistance: mechanisms and clinical implications. 2006 , 14, 18-25	17
1525	Regular aspirin use and retinal microvascular signs: the Blue Mountains Eye Study. 2006 , 24, 1329-35	13
1524	Survey of Clopidogrel Use in a Teaching Hospital. 2006 , 36, 40-43	
1523	Operator volume and outcomes of primary angioplasty for acute myocardial infarction in a single high-volume centre. 2006 , 7, 761-7	12
1522	Stroke management in women. 2006 , 2, 597-603	
1521	The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. 2006 , 17, 93-6	37
1520	Gender differences in stroke care decision-making. 2006 , 44, 70-80	37
1519	Stroke: improving outcome through better diagnosis and treatment. 2006 , 67, 583-7	
1518	A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. 2006 , 1, 11	16

1517	Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?. 2006 , 60, 252-5	1
1516	Multiparameter evidence synthesis in epidemiology and medical decision-making: current approaches. 2006 , 169, 5-35	95
1515	Antiplatelet therapy in peripheral occlusive arterial disease. 2006 , 76, 364-72	
1514	Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. 2006 , 4, 114-20	53
1513	Aspirin in the prevention and treatment of venous thromboembolism. 2006 , 4, 1470-5	66
1512	Arterial disease and venous thrombosis: are they related, and if so, what should we do about it?. 2006 , 4, 1882-5	37
1511	Platelet hyperactivity and risk of recurrent thrombosis. 2006 , 4, 2544-6	18
1510	Opinion: How Should Chronic Medical Therapies be Altered with the Onset of End-Stage Renal Disease and Initiation of Dialysis?. 2006 , 19, 17-20	
1509	Prevention of cardiovascular complications of diabetes mellitus by aspirin. 2004 , 22, 215-26	12
1508	Aspirin resistance in secondary stroke prevention. 2006 , 113, 31-5	48
1507	Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. 2006 , 60, 1129-37	8
1506	Low HDL-cholesterol: Common and under-treated, but which drug to use?. 2006 , 60, 1149-53	7
1505	Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. 2006 , 98, 266-74	171
1504	Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?. 2006 , 98, 275-80	24
1503	Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?. 2006 , 1, 4-8	6
1502	International aspects of global stroke burden. 2006 , 1, 222-3	1
1501	Effects of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood. 2006 , 27, 430-6	18
1500	The impact of a consultant anaesthetist led pre-operative assessment clinic on patients undergoing major vascular surgery. 2006 , 61, 234-9	36

1499	General practitioners' ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database. 2006 , 62, 218-24	14
1498	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. 2006 , 5, 295-309	195
1497	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. 2006 , 69, 2057-63	316
1496	What's new in stroke? The top 10 for 2004/05. 2006 , 54, 674-9	1
1495	Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. 2006 , 48, 270-301	42
1494	Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease. 2006 , 29, 144-8	3
1493	Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy. 2006 , 29, 244-8	2
1492	Aspirin and statin medication decreases the risk of myocardial infarction associated with LTA and NFKBIL1 polymorphisms. 2006 , 1, 237-249	
1491	Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. 2006 , 23, 2691-708	35
1490	Evaluation of platelet function in aspirin treated patients with CAD. 2006 , 21, 241-7	14
1489	Prognosis at 6 months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the Prevenir III study. 2006 , 20, 55-61	5
1488	Gerinnungsaktive Medikamente zur Sekundärprophylaxe bei pAVK. 2006 , 11, 341-346	1
1487	Current developments in anti-platelet therapy. 2006 , 156, 472-80	7
1486	Aspirin resistance - does it clinically matter?. 2006 , 95, 505-10	8
1485	Perceptions of Canadian vascular surgeons toward pharmacological risk reduction in patients with peripheral arterial disease. 2006 , 20, 555-63	18
1484	[Chronic critical ischemia of the lower leg: pretherapeutic imaging and methods for revascularization]. 2006 , 46, 962-72	
1483	What determines the cost-effectiveness of diabetes screening?. 2006 , 49, 1536-44	44
1482	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?. 2006 , 373, 1-17	28

1481	The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke. 2006 , 8, 221-7	2
1480	Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. 2006 , 8, 13-21	
1479	Use of antiplatelet drugs in secondary prevention in patients with atherothrombotic disease. 2006 , 32, 182-8	1
1478	Coronary heart disease: How do the benefits of Ω fatty acids compare with those of aspirin, alcohol/red wine, and statin drugs?. 2006 , 83, 985-997	3
1477	New strategies in the medical treatment of carotid artery disease. 2006 , 8, 33-7	4
1476	Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?. 2006 , 8, 301-6	7
1475	Issues with care in the elderly patient presenting with acute ischemia. 2006 , 3, 51-6	4
1474	Secondary prevention of stroke by blood pressure-lowering treatment. 2006 , 8, 317-23	3
1473	Antiplatelet agents and perioperative bleeding. 2006 , 53, S103-12	49
1472	Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. 2006 , 73, 379-87	64
1471	Managing risk factors for atherosclerosis in critical limb ischaemia. 2006 , 32, 478-83	21
1470	Gastrointestinal Considerations in Patients with Cardiovascular Disease Using Nonopioid Analgesics for Mild-to-Moderate Pain or Cardioprotection. 2006 , 97, 17-22	58
1469	Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. 2006 , 97, 23-9	23
1468	Frequency of aspirin resistance in a community hospital. 2006 , 98, 577-9	53
1467	Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. 2006 , 98, 746-50	66
1466	Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. 2006 , 98, 1156-9	86
1465	Current options in platelet function testing. 2006 , 98, 4N-10N	146
1464	Aspirin resistance or variable response or both?. 2006 , 98, 11N-17N	25

1463	Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures. 2006 , 98, 25N-32N	17
1462	Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. 2006 , 98, 33N-38N	5
1461	Evolving management of ST-segment elevation myocardial infarction: update on recent data. 2006 , 98, 10Q-21Q	9
1460	Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica. 2006 , 6, 31A-40A	
1459	Antiagregación oral e intervencionismo coronario percutáneo. 2006 , 6, 49H-56H	
1458	Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. 2006 , 147, 220-7	14
1457	Antithrombotic therapy: standard therapy in essential hypertension?. 2006 , 49, 11-5	4
1456	Aspirin resistance: truth or dare. 2006 , 112, 733-43	33
1455	Duration of hospital participation in a nationwide stroke registry is associated with improved quality of care. 2006 , 6, 20	18
1454	Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. 2006 , 4, 22	130
1453	Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. 2006 , 26, 1379-87	24
1452	Cardiovascular risks of cyclooxygenase inhibition. 2006 , 26, 919-38	8
1451	Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. 2006 , 54, 3306-9	207
1450	Evidence-based sepsis therapy: a hospitalist perspective. 2006 , 1, 285-95	8
1449	National Stroke Association guidelines for the management of transient ischemic attacks. 2006 , 60, 301-13	155
1448	Treatment of angina: a commentary on new therapeutic approaches. 2006 , 8, A20-A25	2
1447	A survey on adherence to secondary ischemic stroke prevention. 2006 , 28, 16-20	38
1446	Aspirin for prevention of stroke in atrial fibrillation. 2006 , 37, 1640	1

1445	The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit?. 2006 , 114, 861-6	66
1444	Long-term anticoagulant therapy in patients with coronary artery disease. 2006 , 27, 913-9	18
1443	Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?. 2006 , 3, 234-5	9
1442	Sex difference in the antiplatelet effect of aspirin in patients with stroke. 2006 , 40, 812-7	23
1441	The charisma of subgroups and the subgroups of CHARISMA. 2006 , 354, 1744-6	51
1440	Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. 2006 , 57, 171-80	11
1439	Acetylsalicylic acid. 2006 , 15-29	
1438	Predictors of rehospitalization after acute coronary syndromes. 2006 , 63, 367-72	6
1437	Evolving perspectives on clopidogrel in the treatment of ischemic stroke. 2006 , 11, 245-8	11
1436	Platelet function and pharmacologic inhibition. 2006 , 40, 261-7	16
1435	Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. 2006 , 15, 339-43	24
1434	Why is cardiovascular health important in menopausal women?. 2006 , 9 Suppl 1, 13-8	45
1433	Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. 2006 , 92, 1047-54	43
1432	Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. 2006 , 13, 989-96	113
1431	What price pain relief?. 2006 , 113, 2868-70	14
1430	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. 2006 , 114, 2871-91	93
1429	Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes	869
1428	Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?. 2006 , of 17, 385-92. 2006 , 37, 1583-633	69

1427	Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. 2006 , 113, 2566-8	6
1426	Cost-effectiveness of hospital pay-for-performance incentives. 2006 , 63, 495-725	38
1425	Adventures in vascular biology: a tale of two mediators. 2006 , 361, 735-59	73
1424	Controversial treatment of atherosclerotic renal vascular disease: the cardiovascular outcomes in renal atherosclerotic lesions trial. 2006 , 48, 350-6	19
1423	Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery. 2006 , 10, 25-31	24
1422	Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes. 2006 , 82, 224-7	2
1421	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). 2006 , 13, 646-54	28
1420	Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?. 2006 , 17, 1-6	39
1419	Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. 2006 , 27, 519-26	221
1418	Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. 2006 , 29, 2252-6	139
1417	Aspirin prophylaxis and the prevalence of anaemia. 2006 , 35, 514-7	10
1416	Review: Aspirin and diabetes. 2006 , 6, 74-82	1
1415	Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. 2006 , 37, 2153-8	162
1414	Activation of platelet function through G protein-coupled receptors. 2006 , 99, 1293-304	464
1413	Evidence, education and practice. 2006 , 22, 342-9	4
1412	ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. 2006 , 113, 1474-1547	103
1411	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). 2006 , 114, 2850-70	286
1410	Antiplatelet therapy and the vascular tree. 2006 , 92, 3-4	

1409	Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. 2006 , 96, 675-7	45
1408	Expression of functional recombinant mosquito salivary apyrase: a potential therapeutic platelet aggregation inhibitor. 2006 , 17, 178-84	44
1407	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. 2006 , 354, 1706-17	2120
1406	ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). 2006 , 13, e463-654	2378
1405	Therapy for early reperfusion after stroke. 2006 , 3, 656-63	15
1404	Aspirin and clopidogrel resistance: an emerging clinical entity. 2006 , 27, 647-54	250
1403	Mortality and vascular outcomes in patients treated for thyroid dysfunction. 2006 , 91, 2159-64	109
1402	Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease. 2006 , 29, 1973-80	5
1401	Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. 2006 , 113, 2572-8	29
1400	My health: whose responsibility? Low-dose aspirin and older people. 2006 , 4, 755-64	1
1399	Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. 2006 , 27, 1038-47	608
1398	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. 2007 , 8, 2267-77	9
1397	Clinical implications of aspirin resistance. 2007 , 5, 969-75	10
1396	Treating the metabolic syndrome. 2007 , 5, 491-506	41
1395	The argument to support broader application of extracranial carotid artery stent technology. 2007 , 116, 1602-10; discussion 1610	3
1394	Effect of drug combinations on admission for recurrent myocardial infarction. 2007 , 93, 1226-30	14
1393	The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 2007 , 56, 3014-9	174
1392	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction), developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and th. 2007 , 116, e148-304	927

1391	Food intake enhances thromboxane receptor-mediated platelet activation in type 2 diabetic patients but not in healthy subjects. 2007 , 30, 138-40	9
1390	Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?. 2007 , 4, e157	11
1389	Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. 2007 , 7, 395-403	23
1388	Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. 2007 , 29, 251-7	23
1387	Antiplatelet medication management in patients hospitalized with ischemic stroke. 2007 , 64, 2250-6	6
1386	A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary care. 2007 , 83, 602-5	5
1385	Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. 2007 , 32, 2369-74	17
1384	Antithrombotic treatment in atrial fibrillation. 2007 , 93, 39-44	21
1383	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association: response to Buse et al. 2007 , 30, e57; author reply e58	8
1382	How evidence-based are the recommendations in evidence-based guidelines?. 2007 , 4, e250	101
1381	Reduction of disability after stroke is a more informative predictor of long-time survival than initial disability status. 2007 , 29, 417-23	7
1380	Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. 2007 , 38, 1881-5	240
1379	Combination shows no advantage over aspirin alone. 2007 , 334, 1020	
1378	Acute coronary syndromes without ST segment elevation. 2007 , 334, 1265-9	8
1377	Doctors and demons. 2007 , 68, 162	1
1376	Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight). 2007 , 9, A25-A31	
1375	Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. 2007 , 357, 217-27	287
1374	Atherothrombosis--wave goodbye to combined anticoagulation and antiplatelet therapy?. 2007 , 357, 293-6	16

1373	Evaluation and management of transient ischemic attack: an important component of stroke prevention. 2007 , 4, 310-8	12
1372	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. 2007 , 21, 183-211	94
1371	Is there a link between aspirin therapy and stroke severity?. 2007 , 3, 12-3	2
1370	Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. 2007 , 16, 36-44	66
1369	Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA. 2007 , 334, 901	2
1368	Chapter 1: Introduction. 2007 , 14, S2-S113	
1367	Drug evaluation of clopidogrel in patients with ischemic stroke. 2007 , 8, 2825-38	6
1366	Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. 2007 , 18, 414-23	42
1365	Platelet activation in bypass surgery for critical limb ischemia. 2007 , 41, 322-9	3
1364	Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. 2007 , 41, 737-41	25
1363	Antithrombotic treatment for peripheral arterial disease. 2007 , 93, 303-8	16
1362	Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 2007 , 115, 2549-69	507
1361	Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 2007 , 115, 3156-64	315
1360	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. 2007 , 115, 114-26	552
1359	Antiplatelet agents and anaesthesia. 2007 , 7, 157-161	8
1358	Conundrums in the combined use of anticoagulants and antiplatelet drugs. 2007 , 116, 305-15	21
1357	Optimal Dosing of Acetylsalicylic Acid. 2007 , 140, 53-55	
1356	Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II. 2007 , 1, 79-90	5

1355	Diabetic neuropathy. 2007 , 30, 1027-32	15
1354	ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on carotid stenting. 2007 , 12, 35-83	51
1353	Peripheral arterial disease is cardiovascular time bomb. 2007 , 7, 236-239	10
1352	BIBLIOGRAPHY. 2007 , 417-599	
1351	Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. 2007 , 115, 2196-207	169
1350	A comprehensive view of sex-specific issues related to cardiovascular disease. 2007 , 176, S1-44	280
1349	Cardiovascular Pharmacogenomics. 2007 , 20, 265-276	2
1348	Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. 2007 , 128, 143-9	48
1347	Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). 2007 , 23, 368-80	145
1346	Effect of sarpogrelate, a 5-HT _{2A} antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. 2007 , 24, 264-70	36
1345	Dental management of patients receiving anticoagulation or antiplatelet treatment. 2007 , 49, 253-8	54
1344	UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. 2007 , 17, 571-9	24
1343	Aspirin for primary prevention of cardiovascular disease in older persons: where is the evidence?. 2007 , 3, 159-164	
1342	Peripheral Arterial Disease. 2007 ,	
1341	Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A ₂ suppression in LDLR KO mice. 2007 , 109, 3291-6	34
1340	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. 2007 , CD005158	14
1339	Posttreatment ultrasound-detected residual venous thrombosis: a risk factor for recurrent venous thromboembolism and mortality. 2007 , 13, 403-8	7
1338	Antiplatelet therapy in type 2 diabetes mellitus. 2007 , 14, 124-31	34

1337	Mortality and Vascular Outcomes in Patients Treated for Thyroid Dysfunction. 2007 , 2007, 172-174	
1336	Stratégie de prise en charge des syndromes coronariens aigus. 2007 , 2, 1-13	
1335	Traitement des syndromes coronaires aigus avec et sans sus-ST. 2007 , 2, 1-19	
1334	Point-of-Care Monitoring for Optimal Antiplatelet Therapy in Acute Clinical Settings. 2007 , 6, 208-212	1
1333	Myocardial Ischemia and Infarction. 2007 , 35, 127-144	
1332	Dual antiplatelet therapy in high-risk patients. 2007 , 9, D3-D9	6
1331	[Medical treatment in peripheral arterial disease: a professional practice study in 262 patients]. 2007 , 28, 71-8	1
1330	[Antiplatelet agents and digestive endoscopic procedures]. 2007 , 28, 581-3	
1329	Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. 2007 , 119, 209-16	21
1328	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERify Thrombosis risk ASsessment (VERITAS) study. 2007 , 119, 277-84	174
1327	Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. 2007 , 119, 517-24	31
1326	Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. 2007 , 119, 555-62	39
1325	Aspirin failure course during exercise and its connection with soluble CD40L. 2007 , 119, 679-86	12
1324	Aspirin resistance: what, why and when?. 2007 , 119, 551-4	22
1323	Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. 2007 , 120, 161-72	19
1322	Aspirin resistance. 2007 , 120, 337-46	45
1321	The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. 2007 , 120, 353-9	20
1320	Variation and importance of aspirin resistance in patients with known cardiovascular disease. 2007 , 120, 477-84	29

1319	Measuring antiplatelet drug effects in the laboratory. 2007 , 120, 323-36	153
1318	Platelet adhesion in atrial fibrillation. 2007 , 120, 623-9	8
1317	Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. 2007 , 120, 671-7	12
1316	Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 , 121, 413-8	33
1315	COX-2 in play at the AHA and the FDA. 2007 , 28, 303-7	35
1314	Recent FDA warning of the concomitant use of aspirin and ibuprofen and the effects on platelet aggregation. 2007 , 10, 61-3	9
1313	Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction. 2007 , 153, 66.e1-8	1
1312	Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. 2007 , 153, 175-81	205
1311	Dual antiplatelet agent failure: a new syndrome or clinical nonentity?. 2007 , 154, 732-5	11
1310	Aspirin use among adults aged 40 and older in the United States: results of a national survey. 2007 , 32, 403-407	81
1309	Aspirin resistance: is it real? Is it clinically significant?. 2007 , 120, 1-4	282
1308	Aspirin resistance and adverse clinical events in patients with coronary artery disease. 2007 , 120, 631-5	145
1307	Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. 2007 , 120, S3-8; discussion S9	30
1306	Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. 2007 , 83, S27-86	709
1305	Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. 2007 , 84, 1320-5	45
1304	Platelets: the universal killer?. 2007 , 1772, 715-7	5
1303	Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. 2007 , 16, 199-202	26
1302	New developments in secondary stroke prevention: impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on clinical management. 2007 , 16, 263-7	2

1301	[Atherosclerotic stenosis of the internal carotid arteries]. 2007 , 36, 166-75	3
1300	[Acute management and secondary prevention of ischemic stroke]. 2007 , 36, 128-33	2
1299	[Postinfarction management]. 2007 , 36, 999-1006	1
1298	High-dose folate may improve platelet function in acute coronary syndrome and other pathologies associated with increased platelet oxidative stress. 2007 , 69, 12-9	7
1297	A tale of two stents: perioperative management of patients with drug-eluting coronary stents. 2007 , 19, 386-96	15
1296	The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. 2007 , 115, 391-6	15
1295	Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. 2007 , 195, e217-23	35
1294	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. 2007 , 194, 1-45	190
1293	Can aspirin prevent colorectal cancer?. 2007 , 369, 1577-8	9
1292	Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. 2007 , 369, 1603-13	635
1291	Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. 2007 , 370, 493-503	1175
1290	Management of atrial fibrillation. 2007 , 370, 604-18	164
1289	Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. 2007 , 370, 1432-42	870
1288	Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. 2007 , 370, 2054-62	251
1287	Is venous thrombosis a risk factor for arterial thrombosis?. 2007 , 370, 1742-4	12
1286	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. 2007 , 60, 525.e1-525.e64	7
1285	Prevención del infarto cerebral. Medidas en prevención primaria y secundaria. 2007 , 9, 4614-4622	
1284	Protocolo de prevención del infarto cerebral. 2007 , 9, 4638-4642	

1283	Antiagregaci3n plaquetaria en la prevenci3n primaria de la enfermedad cardiovascular. 2007 , 14, 354-360	
1282	The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. 2007 , 23, 663-71	22
1281	Effects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial. 2007 , 23, 1066-72	12
1280	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. 2007 , 23, 1124-30	24
1279	Central Nervous System Ischemia. 2007 , 657-683	1
1278	Variable platelet response to aspirin in patients with ischemic stroke. 2007 , 24, 43-50	27
1277	Antiplatelet therapy: present status and future prospects. 2007 , 2, 1035-40	1
1276	Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. 2007 , 82, 583-93	18
1275	Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. 2007 , 21, 163-6	38
1274	Antagonistas de los receptores plaquetarios GpIIb/IIIa en angiolog3a y cirug3a vascular y endovascular. 2007 , 59, 207-215	1
1273	The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. 2007 , 45, 47-54	32
1272	Acute ST-segment elevation myocardial infarction: critical care perspective. 2007 , 23, 685-707, v	0
1271	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232	247
1270	Medical Treatment of Stable Angina. 2007 , 911-936	
1269	Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. 2007 , 99, 316-28	220
1268	Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. 2007 , 23, 1453-62	14
1267	Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines. 2007 , 4, 151-62	20
1266	Cilostazol for peripheral arterial disease. 2007 , CD003748	23

1265	Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. 2007 , 109, 2285-92	160
1264	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2007 , 14 Suppl 2, E1-40	309
1263	Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. 2007 , 356, 2388-98	1827
1262	Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. 2007 , 25, 1063-82	20
1261	Complete occlusion of extracranial internal carotid artery: clinical features, pathophysiology, diagnosis and management. 2007 , 83, 95-9	36
1260	Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?. 2007 , 116, 293-7	118
1259	Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. 2007 , 5, 441-50	15
1258	Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. 2007 , 18, 16-23	57
1257	ESPRIT study design and outcomes--a critical appraisal. 2007 , 23, 271-3	1
1256	Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. 2007 , 23, 163-73	132
1255	Higher Thrombelastograph platelet reactivity in cardiac surgery patients than in blood donors. 2007 , 41, 321-4	14
1254	The efficacy of aspirin in peripheral arterial disease: an unresolved question. 2007 , 32, 71-2	2
1253	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. 2007 , 1, 339-344	
1252	Management of non-ST-Segment Elevation Myocardial Infarction. 2007 , 91, 683-700; xi	2
1251	Clinical practice. Intermittent claudication. 2007 , 356, 1241-50	86
1250	Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. 2007 , 5, 1167-74	30
1249	Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry. 2007 , 150, 246-52	3
1248	La Aterosclerosis como enfermedad sistēmica. 2007 , 60, 184-195	42

1247	[Association of antiagregants: when and how]. 2007 , 128, 383-9	1
1246	[Diabetes. Living and quality of life]. 2007 , 39, 233-4	
1245	Guía de práctica clínica sobre el tratamiento de las valvulopatías. 2007 , 60, 625.e1-625.e50	10
1244	Ictus. Diagnóstico y tratamiento de las enfermedades cerebrovasculares. 2007 , 60, 753-769	15
1243	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
1242	[Peripheral artery disease: pathophysiology, diagnosis and treatment]. 2007 , 60, 969-82	46
1241	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2007 , 60, 1070.e1-1070.e80	14
1240	Approaches to prevention of cardiovascular complications and events in diabetes mellitus. 2007 , 67, 997-1026	97
1239	Control de los factores de riesgo cardiovascular y utilización de antiagregación plaquetaria en pacientes con diabetes mellitus. 2007 , 54, 76-82	2
1238	Atherosclerosis As a Systemic Disease. 2007 , 60, 184-195	5
1237	Stroke. Diagnosis and Therapeutic Management of Cerebrovascular Disease. 2007 , 60, 753-769	2
1236	ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on	252
1235	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular	1412
1234	Platelet function monitoring in patients with coronary artery disease. 2007 , 50, 1822-34	384
1233	Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 2007 , 50, 1852-6	375
1232	Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. 2007 , CD001820	33
1231	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. 2007 , 30, 162-72	405
1230	Cytochrome P450: Another Player in the Myocardial Infarction Game?. 2007 , 229-280	

1229	Prasugrel versus clopidogrel in patients with acute coronary syndromes. 2007 , 357, 2001-15	4824
1228	Tools for Assessment of Cardiovascular Tests and Therapies. 2007 , 1-34	
1227	Aspirin. 2007 , 1099-1125	3
1226	Unstable Angina and Non-ST Elevation Myocardial Infarction. 2007 , 51-81	
1225	Clinical Tests of Platelet Function. 2007 , 445-474	10
1224	Primary Prevention of Ischemic Heart Disease. 2007 , 178-220	1
1223	Thromboxane Generation. 2007 , 565-574	3
1222	Peripheral Vascular Disease. 2007 , 685-695	
1221	Acetylsalicylic acid decreases the labeling of blood constituents with technetium-99M. 2007 , 58, 187-98	22
1220	Disparities in cardiovascular disease risk and treatment: demographic comparison. 2007 , 55, 415-22	21
1219	Acquired Disorders of Platelet Function. 2007 , 1051-1076	5
1218	From Aspirin to Aspirin Resistance [History, Biochemical Background, Diagnostics and Clinical Relevance. 2007 , 34, 413-419	3
1217	Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. 2007 , 37, 135	7
1216	[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. 2007 , 51, 457-65	1
1215	Peripheral Vascular Disease in Diabetic Peritoneal Dialysis Patients. 2007 , 27, 210-214	9
1214	Antiplatelet therapy in treatment and prevention of thrombus formation. 2007 , 5, 114-121	
1213	Anticoagulation, bleeding and blood transfusion practices in Australasian cardiac surgical practice. 2007 , 35, 760-8	16
1212	Therapeutic Inhibitors of Platelet Aggregation [From Aspirin to Integrin Blockersf. 2007 , 34, 44-54	8

1211	Early local intracoronary platelet activation after drug-eluting stent placement. 2007 , 120, 1886-1991	
1210	Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. 2007 , 70, 388-406	15
1209	Platelet function and antiplatelet therapy. 2007 , 94, 674-82	25
1208	Pharmacokinetic profile of atenolol aspirinate. 2007 , 340, 445-55	2
1207	Preventing another event: role of the hospitalist in discharge stroke prevention. 2007 , 2, 31-8	1
1206	Platelet-neutrophil-interactions: linking hemostasis and inflammation. 2007 , 21, 99-111	460
1205	Evaluation of the TEG platelet mapping assay in blood donors. 2007 , 5, 3	90
1204	Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. 2007 , 8, 21	112
1203	Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. 2007 , 67, 447-55	9
1202	Evidence-based use of medications in patients with coronary artery disease in a rural Australian community. 2007 , 15, 241-6	1
1201	Stroke prevention in atrial fibrillation--things can only get better. 2007 , 64, 575-7	3
1200	Quality indicators for the care of stroke and atrial fibrillation in vulnerable elders. 2007 , 55 Suppl 2, S431-7	13
1199	Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. 2007 , 5, 224-31	13
1198	Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. 2007 , 5, 490-6	200
1197	Prognostic value of annexin A5 -1 C/T polymorphism in a long term follow-up after premature myocardial infarction. 2007 , 5, 862-3	6
1196	Venous thromboembolism and atherosclerosis: is there a link?. 2007 , 5 Suppl 1, 270-5	63
1195	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. 2007 , 5 Suppl 1, 255-63	64
1194	A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. 2007 , 5, 1195-200	26

1193	The critical role of myosin IIA in platelet internal contraction. 2007 , 5, 1516-29	31
1192	Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. 2007 , 5, 1756-65	58
1191	Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?. 2007 , 5, 1835-8	11
1190	Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. 2007 , 5, 2197-203	25
1189	Clinical use of clopidogrel in acute coronary syndrome. 2007 , 61, 473-81	6
1188	The genetics of aspirin resistance. 2007 , 61, 826-34	41
1187	Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. 2007 , 61, 1739-48	11
1186	High prevalence of undiagnosed patients with peripheral arterial disease in patients hospitalised for non-vascular disorders. 2008 , 62, 59-64	18
1185	The challenge of ST-segment elevation myocardial infarction. 2007 , 61, 2079-92	2
1184	Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. 2008 , 62, 287-99	14
1183	Life after ESPRIT: which first-line antiplatelet treatment should we use?. 2007 , 2, 40-2	2
1182	The influence of gender on the effects of aspirin in preventing myocardial infarction. 2007 , 5, 29	26
1181	Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease. 2007 , 27, 1370-8	30
1180	Perioperative use of anti-platelet drugs. 2007 , 21, 241-56	52
1179	Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. 2007 , 1186, 275-80	25
1178	A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. 2007 , 561, 105-11	22
1177	Organising a nurse-driven PAD rehabilitation clinic within the vascular surgical department: what is required and are treatment goals reached--a prospective study?. 2007 , 33, 26-32	7
1176	Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). 2007 , 33 Suppl 1, S1-75	1928

1175	Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. 2007 , 33, 442-50	54
1174	New antiplatelet strategies in atherothrombosis and their indications. 2007 , 34, 10-7	24
1173	Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 2007 , 99, 1496-9	7
1172	Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. 2007 , 99, 1637-42	41
1171	Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. 2007 , 38, 479-88	30
1170	[Long-term management of post acute coronary syndrome with oral antiplatelet therapy]. 2007 , 56 Suppl 1, S29-35	
1169	From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. 2007 , 113, 184-96	35
1168	Pharmacodynamic of cyclooxygenase inhibitors in humans. 2007 , 82, 85-94	136
1167	A novel genetic model of selective COX-2 inhibition: comparison with COX-2 null mice. 2007 , 82, 77-84	16
1166	Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). 2007 , 50, 602-11	94
1165	Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. 2007 , 6, 115-24	178
1164	Atrial fibrillation and stroke prevention. 2007 , 6, 981-93	174
1163	Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists. 2007 , 30, 604-14	6
1162	Management of peripheral arterial disease of the lower extremities. 2007 , 33, 247-56	7
1161	Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure. 2007 , 59, 923-39	119
1160	Pharmacogenomics of platelet responsiveness to aspirin. 2007 , 8, 1413-25	27
1159	A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. 2007 , 63, 421-30	124
1158	The routine electrocardiogram for cardiovascular risk stratification in old age: the Leiden 85-plus study. 2007 , 55, 872-7	25

1157	Contemporary use of clopidogrel in patients with coronary artery disease. 2007 , 9, 257-63	5
1156	Management of coronary artery disease in patients with type 2 diabetes mellitus. 2007 , 9, 264-71	6
1155	Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. 2007 , 32, 97-110	18
1154	Stent fracture in revascularization for symptomatic ostial vertebral artery stenosis. 2007 , 49, 253-7	39
1153	[Perioperative therapy with antiplatelet agents]. 2007 , 56, 592-8	10
1152	Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. 2008 , 30, 120-7	16
1151	Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. 2007 , 21, 375-88	11
1150	Antikoagulation oder Antiaggregation in der Bypasschirurgie bei arterieller Verschlusskrankheit der Beine (pAVK). 2007 , 12, 63-72	2
1149	Geschlechtsverteilung aortaler Gefäßkrankungen. 2007 , 12, 421-428	3
1148	Current strategies for ischemic stroke prevention: role of multimodal combination therapies. 2007 , 254, 1414-26	20
1147	Kardio- und zerebrovaskuläres Risiko bei PAVK. 2007 , 2, IV22-IV29	
1146	Antiplatelet therapy for stroke prevention. 2007 , 9, 312-8	3
1145	Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. 2007 , 9, 409-16	16
1144	How to treat hypertension in patients with peripheral artery disease. 2007 , 9, 190-5	6
1143	Critical limb ischemia. 2007 , 9, 159-70	8
1142	Optimal management of platelet function after coronary stenting. 2007 , 9, 37-45	8
1141	Is there a role for combinations of antiplatelet agents in stroke prevention?. 2007 , 9, 442-50	1
1140	Treatment after myocardial infarction. 2007 , 33, 39-47	3

1139	Schlaganfallmanagement in der Geriatrie. 2007 , 1, 35-40	1
1138	Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamenten freisetzenden Koronarstents (DES). 2007 , 1, 84-111	21
1137	Mortality in peripheral arterial disease: a comparison of patients managed by vascular specialists and general practitioners. 2007 , 22, 639-44	15
1136	Antikoagulation bei Diabetes mellitus. 2007 , 3, 469-482	
1135	Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors. 2008 , 22, 185-91	6
1134	Pharmacist intervention reduces gastropathy risk in patients using NSAIDs. 2008 , 30, 947-54	10
1133	Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. 2008 , 25, 173-8	10
1132	Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial. 2008 , 53, 647-56	10
1131	Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. 2008 , 23, 35-9	14
1130	[Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]. 2008 , 103, 778-87	3
1129	[Critical limb ischemia]. 2008 , 79, 495-506; quiz 507-8	5
1128	[Therapy of chronic stable angina]. 2008 , 49, 57-66; quiz 67-8	
1127	[Secondary prevention after myocardial infarction]. 2008 , 49, 1052-60	0
1126	[European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2]. 2008 , 79, 1180-4, 1186-8, 1190-201	14
1125	Aspirin resistance and diabetes mellitus. 2008 , 51, 385-90	57
1124	Thrombozytenfunktion bei Diabetes mellitus. 2008 , 4, 429-434	
1123	Makroangiopathie bei Diabetes mellitus. 2008 , 3, 29-34	
1122	Aspirin resistance in atherosclerosis. 2008 , 10, 149-57	1

1121	Optimal treatment of the diabetic patient with multivessel disease. 2008 , 10, 272-84	1
1120	Antiplatelet therapy in acute coronary syndromes. 2008 , 10, 327-33	5
1119	Lipid management: considerations in acute coronary syndrome. 2008 , 10, 334-41	
1118	Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?. 2008 , 8, 29-34	5
1117	The heart of new ulm: a vision for the future. 2008 , 1, 310-6	21
1116	New strategies in the medical treatment of carotid artery disease. 2008 , 10, 156-63	2
1115	Antiplatelet agents for secondary prevention of stroke. 2008 , 10, 223-8	
1114	Inflammation in acute ischemic stroke and its relevance to stroke critical care. 2008 , 9, 125-38	72
1113	Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. 2008 , 13, 31-41	1
1112	Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. 2008 , 13, 115-125	
1111	Cardiovascular protection for all individuals at high risk: evidence-based best practice. 2008 , 97, 713-25	8
1110	Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. 2008 , 255, 1679-86	152
1109	Weather-induced ischemia and arrhythmia in patients undergoing cardiac rehabilitation: another difference between men and women. 2008 , 52, 535-47	40
1108	Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. 2008 , 43, 581-8	54
1107	Anticoagulation therapy in glaucoma surgery. 2008 , 246, 891-6	17
1106	Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients. 2008 , 7, 16	18
1105	Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. 2008 , 9, 37	72
1104	Low prevalence and assay discordance of "aspirin resistance" in children. 2008 , 51, 86-92	15

1103	Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. 2008 , 17, 1189-96	106
1102	Introduction: Role of the hospitalist in secondary stroke prevention care. 2008 , 3, S1-S5	
1101	Evidence-based medicine: Review of guidelines and trials in the prevention of secondary stroke. 2008 , 3, S6-S19	1
1100	2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 , 71, E1-40	23
1099	Flow cytometric assessment of platelet aspirin resistance using light scattering. 2008 , 74, 110-7	3
1098	The surgical application of point-of-care haemostasis and platelet function testing. 2008 , 95, 1317-30	24
1097	Progress in secondary stroke prevention. 2008 , 63, 418-27	19
1096	Transient ischemic attack: risk stratification and treatment. 2008 , 52, S27-39	13
1095	Oligo(3-hydroxybutanoate) conjugates with acetylsalicylic acid and their antitumour activity. 2008 , 43, 1785-90	17
1094	Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. 2008 , 22, 107-16	26
1093	A pilot-study to identify the feasibility of an Internet-based coaching programme for changing the vascular risk profile of high-risk patients. 2008 , 73, 67-72	29
1092	Investigating the mechanisms of hyporesponse to antiplatelet approaches. 2008 , 31, I21-7	7
1091	Managing antiplatelet therapy in the ACS patient: straight from the emergency department to you. 2008 , 3 Suppl 2, S15-9	
1090	Peripheral arterial disease and the hospitalist: the rationale for early detection and optimal therapy. 2008 , 3 Suppl 2, S4-8	1
1089	Aggressive management of ischemic stroke: the case for the hospitalist. 2008 , 3 Suppl 2, S9-14	1
1088	Australian Clinical Guidelines for Acute Stroke Management 2007. 2008 , 3, 120-9	24
1087	Stroke and atherothrombosis: an update on the role of antiplatelet therapy. 2008 , 3, 175-81	8
1086	Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. 2006 , 60, 863-6	23

1085	Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 2008 , 21, 283-99	2
1084	Advances in antiplatelet therapy for ACS and PCI. 2008 , 21 Suppl 1, S18-24	5
1083	Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. 2008 , 28, 1285-93	36
1082	Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. 2008 , 28, 1196-203	41
1081	Future innovations in anti-platelet therapies. 2008 , 154, 918-39	115
1080	ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. 2008 , 15, 1304-8	14
1079	Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. 2008 , 6, 1832-4	12
1078	The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. 2008 , 6, 2210-3	11
1077	Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. 2008 , 6, 2035-44	64
1076	Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. 2008 , 23 Suppl 2, S234-6	15
1075	How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes?. 2008 , 25, 1433-9	27
1074	Bleeding time prolonged by daily low-dose aspirin is shortened by one medium dose aspirin. 2008 , 52, 1226-30	3
1073	Antiplatelet drugs. 2008 , 142, 515-28	45
1072	Incidence of fatal adverse drug reactions: a population based study. 2008 , 65, 573-9	210
1071	Pharmacogenetics of aspirin resistance: a comprehensive systematic review. 2008 , 66, 222-32	148
1070	Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. 2008 , 33, 591-601	20
1069	Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. 2008 , 8, 25	42
1068	Aspirin resistance: disparities and clinical implications. 2008 , 28, 999-1018	8

1067	Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. 2008 , 101, 786-9	61
1066	Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention. 2008 , 101, 4D-13D	32
1065	Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. 2008 , 102, 396-400	16
1064	Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease. 2008 , 102, 921-6	32
1063	Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). 2008 , 102, 1285-90	11
1062	Drug-eluting stents and antiplatelet resistance. 2008 , 102, 29J-37J	5
1061	Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation. 2008 , 595, 65-8	7
1060	What does 'best medical therapy' really mean?. 2008 , 35, 139-44	28
1059	Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. 2008 , 7, 41-9	113
1058	Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. 2008 , 7, 915-26	737
1057	Aspirin revisited: helpful or harmful? What is the correct dose for a certain population?. 2008 , 23, 49-50	
1056	Management of hypertension in peripheral arterial disease. 2008 , 50, 238-63	35
1055	A review of therapeutic strategies for risk reduction of recurrent stroke. 2008 , 50, 264-73	12
1054	Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. 2008 , 50, 311-51	14
1053	Antiplatelet therapy for acute ischaemic stroke. 2008 , CD000029	44
1052	Aspirin nonresponse in patients with arterial causes of ischemic stroke: considerations in detection and management. 2008 , 272, 1-7	6
1051	Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. 2008 , 47, 774-781	121
1050	Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons. 2008 , 47, 1108-15	10

1049	Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial. 2008 , 31, 449-58	2
1048	Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. 2008 , 47, 129-37	33
1047	Carotid stenting: risk factors for periprocedural stroke. 2008 , 8, 469-77	7
1046	Biomarkers for the early detection of Parkinson's and Alzheimer's disease. 2008 , 5, 133-6	72
1045	Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. 2008 , 61, 82.e1-82.e49	14
1044	[Efficacy of an intensive prevention programme of coronary heart disease: 5 year follow-up outcomes]. 2008 , 130, 521-5	7
1043	Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. 2008 , 61, 501-513	35
1042	Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. 2008 , 61, 752-764	39
1041	Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. 2008 , 6, 46	45
1040	'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?. 2008 , 6, 47	20
1039	Coronary Atherothrombotic Disease: Progress in Antiplatelet Therapy. 2008 , 61, 501-513	
1038	Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. 2008 , 61, 752-764	8
1037	2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 , 51, 210-47	648
1036	2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. 2008 , 51, 172-209	503
1035	Optimal treatment of carotid artery disease. 2008 , 51, 979-85	37
1034	The role of aspirin in cardiovascular prevention: implications of aspirin resistance. 2008 , 51, 1829-43	218
1033	Reply. 2008 , 52, 580-582	
1032	Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. 2008 , 52, 743-9	256

1031	ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2008 , 52, 1502-17	338
1030	An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. 2008 , 121, 81-7	42
1029	Antithrombotic therapy in peripheral arterial disease. 2008 , 26, 289-98, vii	4
1028	Cilostazol for peripheral arterial disease. 2008 , CD003748	56
1027	Cardio-embolic stroke. 2009 , 93, 719-49	1
1026	Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. 2008 , 359, 1238-51	717
1025	Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. 2008 , 7, 37	154
1024	Chronic antithrombotic therapy in post-myocardial infarction patients. 2008 , 26, 277-88, vii	4
1023	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. 2008 , 12, 809-20	10
1022	Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. 2008 , 117, 1945-54	402
1021	Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. 2008 , 128, 166-71	62
1020	The benefit of aspirin therapy in type 2 diabetes: what is the evidence?. 2008 , 129, 172-9	12
1019	Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. 2008 , 17, 129-33	15
1018	Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats. 2008 , 82, 806-15	22
1017	[New antiplatelet drugs]. 2008 , 37, 1055-68	
1016	A pilot study of resistance to aspirin in stroke patients. 2008 , 15, 1204-9	29
1015	Antiplatelet therapy in management of transient ischemic attack: overview and evidence-based rationale. 2008 , 34, 389-96	2
1014	Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective. 2008 , 35, 5-13	10

1013	Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. 2008 , 155, 382-7	13
1012	The economic consequences of non-evidence-based clopidogrel use. 2008 , 155, 904-9	19
1011	Antiplatelet drug nonresponsiveness. 2008 , 155, 591-9	40
1010	An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. 2008 , 156, 106-11	22
1009	Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. 2008 , 156, 31-6	37
1008	Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. 2008 , 156, 473-6	43
1007	Current antiplatelet therapies: benefits and limitations. 2008 , 156, S3-9	40
1006	Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 2008 , 156, 1080-1088.e1	117
1005	The approach to optimizing stroke care. 2008 , 26, 808-16	8
1004	Antiplatelet therapy for postdischarge medical management of acute coronary syndrome. 2008 , 121, 171-8	2
1003	Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. 2008 , 121, 43-9	156
1002	Aspirin, NSAIDs, and cardiovascular risk: is there a link?. 2008 , 121, e9	0
1001	Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients. 2008 , 40, 3485-8	6
1000	Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?. 2008 , 47, 161-6	19
999	Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. 2008 , 121, 509-17	20
998	Enhancing effect of the (145)Met-allele of GPIb alpha on platelet sensitivity to aspirin under high-shear conditions. 2008 , 123, 331-5	4
997	Potential and priming of platelet activation: a potential target for antiplatelet therapy. 2008 , 29, 352-60	60
996	Intracerebral hemorrhage. 2009 , 93, 767-90	12

995	Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. 2008 , 48, 335-43	37
994	Venous and arterial thrombosis: different sides of the same coin?. 2008 , 19, 476-81	61
993	Morphological changes of ulcerative plaque in patients received carotid angioplasty and stenting (CAS). 2008 , 65, 434-41	5
992	Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. 2008 , 391, 120-2	6
991	Can aspirin resistance be clinically predicted in stroke patients?. 2008 , 110, 110-6	22
990	Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. 2008 , 30, 249-59	20
989	[External validity]. 2008 , 102, 253-9	4
988	Prostanoid and isoprostanoid pathways in atherogenesis. 2008 , 201, 8-16	43
987	Antiplatelet therapy for recurrent stroke prevention: newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT). 2008 , 2, 3-7	3
986	F?rmacos antitromb?ticos en el ?mbito extrahospitalario. 2008 , 10, 1493-1501	
985	Stroke. 2008 , 371, 1612-23	1852
984	Acute myocardial infarction. 2008 , 372, 570-84	466
983	Thromboprophylaxis for patients at high risk of VTE. 2008 , 372, 1037-8	
982	Type 2 diabetes mellitus: prevention of macrovascular complications. 2008 , 6, 323-41	21
981	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf	520
980	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. 2008 , 24, 363-8	5
979	Prevencci?n de la enfermedad cardiovascular en los pacientes diab?ticos: ?qu? 'hay de nuevo?. 2008 , 34, 209-213	0
978	Resistencia al ?cido acetilsalic?lico y sus repercusiones cl?nicas. 2008 , 34, 244-248	

977	Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home. 2008 , 9, 124-7	13
976	Menopause and the menopausal transition. 2008 , 92, 1253-71, xii	24
975	Antiplatelet agents and arterial thrombosis. 2008 , 26, 189-201, vi	8
974	New insights into stroke in chronic kidney disease. 2008 , 15, 338-46	9
973	Peripheral arterial disease: diagnosis and management. 2008 , 83, 944-49; quiz 949-50	11
972	Monitoring aspirin therapy with the Platelet Function Analyzer-100. 2008 , 68, 786-92	8
971	The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk : the pro position. 2008 , 15, 53-7	1
970	Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. 2008 , 8, 91-112	15
969	Secondary stroke prevention: inside the vessels and beyond. 2008 , 22, 113-21	
968	Peripheral arterial disease in the elderly: recognition and management. 2008 , 8, 353-64	26
967	Clinical and therapeutic aspects of vascular dementia. 2008 , 89, 659-70	
966	The additional value of routine electrocardiograms in cardiovascular risk management of older people. 2008 , 26, 147-53	11
965	Anticoagulants for acute ischaemic stroke. 2008 , CD000024	45
964	Current concepts about inhibition of platelet aggregation. 2008 , 19, 565-70	10
963	Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. 2008 , 19, 104-10	32
962	Antithrombotic agents for stroke prevention. 2009 , 94, 1277-94	1
961	Platelet activation and atherothrombosis. 2008 , 358, 1638; author reply 1638-9	25
960	[Medical treatment of patients with clinical peripheral arterial disease at hospital discharge: compliance with the French guidelines and changing practices (COPART I registry)]. 2008 , 33, 1-11	

959	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. 2008 , 5, 766-80	72
958	The interactions between cardiovascular and cerebrovascular disease. 2009 , 94, 1039-57	
957	Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 2008 , 118, 2139-45	86
956	2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. 2008 , 42, 989-1001	11
955	Peripheral artery disease: therapeutic advances. 2008 , 6, 539-53	15
954	Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. 2008 , 31, 363-5	30
953	Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trial. 2008 , 6, 218-27	149
952	Point/Counterpoint: Aspirin should not be promoted for colon cancer prevention: counterpoint. 2008 , 17, 1562-3	6
951	Aspirin: promise and resistance in the new millennium. 2008 , 28, s25-32	72
950	Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. 2008 , 117, 553-9	110
949	Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. 2008 , 117, 569-73; discussion 573	34
948	Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. 2008 , 117, 192-9	43
947	ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2008 , 118, 1894-909	350
946	Frequency of a low ankle brachial index in the general population by age, sex and deprivation: cross-sectional survey of 28,980 men and women. 2008 , 15, 370-5	27
945	Aspirin resistance in cardiovascular disease. 2008 , 336, 166-7	8
944	Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. 2008 , 118, 538-51	37
943	Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?. 2008 , 31 Suppl 2, S222-5	6
942	Haemorrhagic stroke during anti-platelet therapy. 2008 , 42, 12-5	8

941	Antiplatelet therapy in acute coronary syndromes. 2008 , 10, A4-A12	2
940	Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 630S-669S	273
939	Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe. 2008 , 51, 425-33	4
938	Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. 2008 , 179, 895-900	30
937	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. 2008 , 179, 920-6	30
936	Impact on mortality following first acute myocardial infarction of distance between home and hospital: cohort study. 2008 , 94, 1141-6	33
935	Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. 2008 , 39, 1358-63	88
934	Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. 2008 , 39, 1638-46	40
933	Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. 2008 , 39, 1740-5	186
932	Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published trials. 2008 , 39, 2817-23	34
931	Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 199S-233S	350
930	Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 546S-592S	595
929	Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. 2008 , 10, 397-403	23
928	Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. 2008 , 19, 335-41	26
927	Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. 2008 , 5, 138-44	83
926	Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?. 2008 , 42, 790-805	34
925	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. 2008 , 29, 2909-45	1774
924	ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. 2008 , 103, 2890-907	117

923	Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. 2008 , 117, 816-22	21
922	Standards of medical care in diabetes--2008. 2008 , 31 Suppl 1, S12-54	1381
921	2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writ. 2008 , 117, 296-329	858
920	The importance of conservative measures in peripheral arterial disease: an update. 2008 , 59, 529-33	0
919	Translational therapeutics of dipyridamole. 2008 , 28, s39-42	86
918	Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. 2008 , 2, 387-405	9
917	Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. 2008 , 24, 2509-22	30
916	Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. 2008 , 20, 92-9	117
915	Statin therapy for stroke prevention. 2008 , 39, 1042-8	51
914	Costs and health care system issues. 2009 , 92, 373-88	
913	Abstract. 2008 , 16, 101-164	8
912	Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. 2008 , 294, H1562-70	46
911	Aspirin resistance: biological and clinical implications. 2008 , 13, 5-12	18
910	Nonsteroidal anti-inflammatory drugs. 2008 , 1307-1316	
909	Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. 2008 , 3, 1373-8	27
908	Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study. 2008 , 59, 269-77	2
907	Heartwatch: a secondary prevention programme in primary care in Ireland. 2008 , 15, 651-6	10
906	Aspirin chemoprevention: one size does not fit all. 2008 , 117, 2844-6	12

905	The role of percutaneous revascularization for renal artery stenosis. 2008 , 13, 141-56	35
904	Aspirin and Diabetes Mellitus: revisiting an old player. 2008 , 2, 37-42	11
903	Epidemiological implications of primary and secondary stroke prevention. 2009 , 92, 389-405	
902	Thienopyridine therapy influences late outcome after coronary stent implantation. 2008 , 59, 172-8	10
901	Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. 2008 , 40, 296-302	2
900	Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. 2008 , 117, 2544-45	394
899	Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients. 2008 , 21, 287-301	1
898	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. 2008 , 118, 1705-12	174
897	Targeted versus global approaches to the management of hypercholesterolaemia. 2008 , 128, 248-54	3
896	Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. 2008 , 117, 2875-83	75
895	Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. 2008 , 93, 3671-89	128
894	Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. 2008 , 120, 67-78	
893	Stroke and the female brain. 2008 , 4, 22-33	67
892	Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. 2008 , 34, 93-108	58
891	Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. 2008 , 39, 1827-33	95
890	The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. 2008 , 6, 95-107	21
889	Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. 2008 , 19, 119-24	58
888	Aspirin resistance: myth or major problem?. 2008 , 68, 257-9	5

887	Peripheral Arterial Disease: Diagnosis and Management. 2008 , 83, 944-950	22
886	Secondary stroke prevention: from guidelines to clinical practice. 2008 , 100, 1125-37	16
885	When and how to discontinue antiplatelet therapy. 2008 , 10, A35-A41	11
884	Variability of response to antiplatelet therapy. 2008 , 10, A21-A27	11
883	Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. 2008 , CD006503	9
882	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 708S-775S	88
881	Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. 2008 , 106, 469-77	34
880	Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 815S-843S	118
879	Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. 2008 , 72, 420-6	20
878	Essential Fatty Acids: Physiology and Clinical Significance. 2008 , 1	
877	Clopidogrel use in coronary heart disease and percutaneous coronary intervention. 2008 , 56, 689-700	3
876	Outcomes associated with combined antiplatelet and anticoagulant therapy. 2008 , 133, 948-54	60
875	[Coronary artery disease and inflammation]. 2008 , 97, 524-32	
874	The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 776S-814S	196
873	Ginkgo biloba for intermittent claudication. 2008 ,	
872	Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 670S-707S	123
871	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 234S-256S	186
870	Antiplatelet therapy in percutaneous coronary intervention. 2008 , 10, A13-A20	6

869	The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. 2008 , 337, a1840	629
868	Sedation and Analgesia Medications. 241-259	
867	Platelet inhibitors: what are the data in women?. 2008 , 16, 23-9	0
866	Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. 2008 , 30, 372-8	33
865	Comparison of four laboratory methods to assess aspirin sensitivity. 2008 , 19, 120-3	19
864	Management of lower extremity peripheral arterial disease. 2008 , 28, 349-57	62
863	Prognostic value of hypotensive blood pressure response during single-stage exercise test on long-term outcome in patients with known or suspected peripheral arterial disease. 2008 , 19, 603-7	12
862	Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography. 2008 , 15, 458-60	1
861	Ordinal reanalysis of the SHEP trial. 2008 , 39, e145; author reply e146	3
860	Coronary artery stents: II. Perioperative considerations and management. 2008 , 107, 570-90	87
859	Aspirin resistance: focus on clinical endpoints. 2008 , 52, 475-84	18
858	The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease. 2008 , 23, 487-93	19
857	Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. 2008 , 26, 844-52	17
856	Early aggressive vs. initially conservative treatment in elderly patients with non-ST-elevation acute coronary syndrome: the Italian Elderly ACS study. 2008 , 9, 217-26	10
855	Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. 2008 , 19, 235-9	22
854	Acute ischemic coronary artery disease and ischemic stroke: similarities and differences. 2008 , 15, 137-49	16
853	Central Nervous System (CNS). 2008 , 1	
852	Management of peripheral arterial disease in the elderly: focus on cilostazol. 2008 , 3, 17-23	10

851 Adjunctive pharmacotherapy during PCI. **2008**, 53-64

850 Urgent need for secondary stroke prevention after transient ischemic attack. **2008**, 23, 131-40 3

849 A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. **2008**, 3, e2852 25

848 Peripheral Arterial Disease Evaluation in the Saudi Project for Assessment of Coronary Events Registry Reveals a Missed Opportunity in Preventing the Adverse Cardiovascular Outcomes: A Pilot Study (SPACE-PAD-I). **2008**, 2, CMC.S421

847 Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. **2008**, 337, a1198 64

846 Current role of medical treatment and invasive management in carotid atherosclerotic disease. **2008**, 21, 133-8 8

845 Cryptogenic stroke in a patient with a PFO: a decision analysis. **2008**, 335, 457-64 5

844 Antiplatelet drugs in cardiological practice: established strategies and new developments. **2008**, 4, 637-45 24

843 Peripheral arterial disease in the elderly. **2007**, 2, 645-54 38

842 Heart rate variability in patients with stable coronary artery disease and aspirin resistance. **2008**, 49, 413-22 6

841 Cardiovascular Disease Prevention. **2008**, 538-549

840 Medical Treatment of Peripheral Arterial Disease. **2008**, 163-168

839 Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. **2008**, 189, 105-9 47

838 Will prasugrel supersede clopidogrel for acute coronary syndromes?. **2008**, 188, 381-2 5

837 Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside. **2008**, 2, 397-407

836 Antiplatelet Resistance Does it Exist and how to Measure it?. **2009**, 3, CMC.S2159 2

835 Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. **2009**, 5, 101-19 11

834 Stroke prevention and stroke thrombolysis: quantifying the potential benefits of best practice therapies. **2009**, 190, 678-82 3

833 Koronare Herzkrankheit und akutes Koronarsyndrom. **2009**, 13-71

832 Venous and arterial thrombosis: Two aspects of the same disease?. **2009**, 1, 1-6 37

831 Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. **2009**, 16, 155-63 19

830 Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. **2009**, 1, CMT.S1170

829 Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. **2009**, 45, 248-53 14

828 Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. **2009**, 5, 677-91

827 Acute treatment of transient ischemic attack and minor stroke. 239-249

826 Natural History and Medical Management of Chronic Lower Extremity Ischemia. **2009**, 119-136

825 Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. **2009**, 1, CMT.S2208

824 [Acute massive gastrointestinal bleeding in the elderly]. **2009**, 46, 250-8 1

823 Linking joint commission inpatient core measures and national patient safety goals with evidence. **2009**, 22, 103-11 12

822 Methods of assessing treatments. 223-238

821 Secondary prevention. 272-282

820 Ensuring safety through evidence-based medicine. 173-192

819 Acute therapies and interventions. 230-242

818 Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. **2009**, 25, 2631-41 16

817 Predicting recurrent stroke after minor stroke and transient ischemic attack. **2009**, 7, 1273-81 8

816 Augmentation of U46619 induced human platelet aggregation by aspirin. **2009**, 20, 111-9 2

815	How optimal is the medical management of patients prior to major reconstructive vascular surgery? The results of a cross-sectional study. 2009 , 43, 238-43	7
814	Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. 2009 , 32, 531-40	97
813	The ankle-brachial index as a biomarker of cardiovascular risk: it's not just about the legs. 2009 , 120, 2033-5	28
812	Cardiovascular risk and management in chronic kidney disease. 2009 , 5, 287-96	49
811	Antiplatelet agents. 2009 , 267-72	22
810	Novel preventive and therapeutic strategy for post-stroke pneumonia. 2009 , 9, 1187-200	44
809	Preventing premature mortality in chronic diseases for South Asians in the UK and beyond. 2009 , 102, 459-63	3
808	NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. 2011 , 6, e16780	35
807	Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008. 2011 , 6, e26917	32
806	Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study. 2012 , 7, e30094	22
805	Association of primary care characteristics with variations in mortality rates in England: an observational study. 2012 , 7, e47800	21
804	The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. 2012 , 7, e52145	54
803	Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. 2013 , 8, e52952	25
802	Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. 2013 , 8, e57578	48
801	The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. 2013 , 8, e65754	9
800	Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. 2013 , 8, e71150	27
799	Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. 2014 , 9, e110124	41
798	Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. 2016 , 11, e0148069	6

797	Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies. 2016 , 11, e0164704	33
796	Persistent smoking after a cardiovascular event: A nationwide retrospective study in Korea. 2017 , 12, e0186872	5
795	Diabetes mellitus type 2 in adults. 2020 , 23, 4-102	9
794	Hemorrhagic manifestations of cerebral amyloid angiopathy: from pathogenesis to clinical significance. 2018 , 10, 4-11	9
793	Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. 2016 , 43, 482-487	7
792	What Do the Guidelines Really Say About Aspirin?. 2018 , 45, 228-230	2
791	Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study. 2018 , 20, 354-362	1
790	The effect of aspirin on kidney allograft outcomes; a short review to current studies. 2017 , 6, 110-117	7
789	Direct-acting Anticoagulants in Chronic Coronary Syndromes. 2020 , 15, 1-7	1
788	[Clopidogrel resistance in cerebrovascular disease -- results of one-year follow-up]. 2015 , 156, 53-9	1
787	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. 2020 , 25, 4103	59
786	The Case for Early Detection and Integrated Intervention in Patients With Peripheral Arterial Disease and Intermittent Claudication. 2003 , 10, 601-613	4
785	Aspirin therapy is still underutilized among patients with type 2 diabetes. 2006 , 50, 1014-9	1
784	[Cardiovascular prevention in diabetic patients: an evidenced-based review]. 2007 , 51, 312-8	4
783	Acetylsalicylic acid and labeling of blood constituents with technetium-99m. 2005 , 48, 163-168	3
782	[Contemporary paradigm of rational stroke treatment]. 2016 , 116, 82-87	1
781	[Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease]. 2019 , 59, 43-51	1
780	Bleeding complication after endoscopic submucosal dissection of gastric neoplasm. 2019 , 8, 123-126	1

779	Biochemical aspirin resistance is associated with increased stroke severity and infarct volumes in ischemic stroke patients. 2017 , 8, 77086-77095	11
778	Platelet function-guided modification in antiplatelet therapy after acute ischemic stroke is associated with clinical outcomes in patients with aspirin nonresponse. 2017 , 8, 106258-106269	8
777	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. 2016 , 7, 39143-39147	10
776	Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study. 2019 , 81, 359-373	3
775	Continuing aspirin before coronary artery bypass grafting surgery: old fears challenged by new evidences. 2016 , 4, S34	3
774	Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window. 2017 , 5, 464	5
773	Improving the gastrointestinal tolerability of aspirin in older people. 2006 , 1, 33-9	9
772	Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?. 2005 , 1, 111-7	7
771	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). 2006 , 2, 379-87	3
770	Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. 2007 , 3, 229-34	190
769	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. 2019 , 25, 4063-4084	65
768	Antithrombotic Therapy in Carotid Artery Disease. 2020 , 26, 2725-2734	1
767	High Risk of One-year Stroke Recurrence in Patients with Younger Age and Prior History of Ischemic Stroke. 2019 , 16, 250-257	5
766	Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. 2009 , 5, 177-86	24
765	Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities. 2019 , 19, 19-32	5
764	COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. 2010 , 4, 198-205	2
763	The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies. 2008 , 6, 150-159	36
762	The Needs and Barriers of Medication-Taking Self-Efficacy Among Poststroke Patients: Qualitative Study. 2019 , 2, e14399	3

761	An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. 2009 , 11, e51	48
760	Corrected and republished from: Regional anesthesia and antithrombotic agents: instructions for use. 2020 , 86, 341-353	2
759	Medical therapy does not confer stroke prevention for all patients: identification of high-risk patients with asymptomatic carotid stenosis is still needed. 2019 , 38, 372-380	5
758	Risk factors for venous and arterial thrombosis. 2011 , 9, 120-38	210
757	Antiplatelet agents in clinical practice and their haemorrhagic risk. 2013 , 11, 349-56	18
756	?????????????????????????. 2003 , 14, 316-325	1
755	A real way of reducing coronary heart disease mortality in Russia. 2010 , 1, 11-17	3
754	Diabetes and red blood cell parameters. 2017 , 2, 001-009	2
753	Strategy of Rational Therapy of Acute Respiratory Infections in Patients with Comorbidity. 2020 , 8, 77-83	1
752	Angina in the Elderly. 2008 , 269-292	5
751	Management of the Older Patient After Myocardial Infarction. 2008 , 327-350	2
750	Ventricular Arrhythmias in the Elderly. 2008 , 605-626	3
749	Ultrasound control of the growth of thrombus -potential for the embolus growth suppression & the reocclusion prevention-. 2011 , 38, 549-555	3
748	Challenges, solutions and future directions in the evaluation of service innovations in health care and public health. 2016 , 4, 1-136	57
747	An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. 2014 , 18, 1-368, v-vi	41
746	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. 2018 , 22, 1-76	6
745	The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III Study - Stroke Specific Module. 2008 , 50, 446-454	10
744	Distribution of Ankle-Brachial Index among Inpatients with Cardiovascular Disease: Analysis Using the Kumamoto University Hospital Medical Database. 2016 , 9, 22-9	4

743	Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report. 2011 , 17, 4048-51	2
742	Geographic differences in low-dose aspirin-associated gastroduodenal mucosal injury. 2015 , 21, 7709-17	10
741	Antiplatelet Effectivity between Aspirin with Honey on Cardiovascular Disease Based on Bleeding Time Taken on Mice. 2019 , 7, 3416-3420	4
740	Antithrombotic regimens in patients after coronary artery bypass grafting and coronary endarterectomy. 2020 , 67, 115-120	1
739	Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. 2013 , 10, 21-7	11
738	Percutaneous coronary intervention in nonagenarians: pros and cons. 2013 , 10, 82-90	8
737	Spontaneous coronary artery dissection-A review. 2015 , 5, 37-48	131
736	Prevention of colorectal cancer and dietary management. 2013 , 2, 13	19
735	Prevalence and Clinical Characteristics of Aspirin Resistance in the Patients with Type 2 Diabetes Mellitus. 2008 , 32, 53	2
734	Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study. 2016 , 48, 26-31	14
733	Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital. 2011 , 31, 371-5	9
732	Antiplatelet drugs and the perioperative period: What every urologist needs to know. 2009 , 25, 296-301	17
731	Percutaneous native kidney biopsy in patients receiving antiplatelet agents- is it necessary to stop them routinely?. 2015 , 25, 129-32	2
730	Effect of antiplatelet therapy on mortality and acute lung injury in critically ill patients: A systematic review and meta-analysis. 2016 , 19, 626-637	10
729	Stroke management. 2011 , 14, S82-96	24
728	Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran. 2017 , 12, 144-153	6
727	Influence of aspirin on post-extraction bleeding - A clinical study. 2014 , 4, S63-7	8
726	Aspirin resistance and ischemic heart disease on Iranian experience. 2012 , 1, 33	2

725	Risk Factors, Vascular Lesion Distribution, Outcome and Recurrence of Strokes Due to Intracranial Atherosclerosis: One Year Data from Hyderabad Stroke Registry. 2017 , 20, 387-392	4
724	Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. 2019 , 22, 147-152	5
723	Preintensive care: Thrombolytic (streptokinase or tenecteplase) in ST elevated acute myocardial infarction at peripheral hospital. 2019 , 8, 62-71	8
722	Review of Medical Treatment of Stable Ischemic Heart Disease. 2014 , 05, 249-259	1
721	Aspirin resistance in young men with Type 2 diabetes. 2014 , 04, 72-76	1
720	Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. 2014 , 5, 115-27	25
719	Aspirin use for primary prophylaxis: Adverse outcomes in non-variceal upper gastrointestinal bleeding. 2016 , 8, 501-7	3
718	State of the art: optimal medical therapy - competing with or complementary to revascularisation in patients with coronary artery disease?. 2017 , 13, 751-759	4
717	Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial. 2018 , 14, e580-e587	2
716	Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. 2014 , 10, 38-46	86
715	Making sense of the recent meta-analytical confusion concerning the safety of drug-eluting stents. 2007 , 3, 381-5	12
714	Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. 2012 , 8, 672-8	62
713	2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 10, 1024-94	195
712	2018 ESC/EACTS Guidelines on myocardial revascularization. 2019 , 14, 1435-1534	180
711	Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence. 2020 , 12, 408-450	2
710	A study of the changes in the cause of peptic ulcer bleeding. 2012 , 4, 323-7	6
709	Small bowel ulcerative lesions are common in elderly NSAIDs users with peptic ulcer bleeding. 2014 , 6, 612-9	3
708	Diagnostic and therapeutic challenge of heart failure after liver transplant: Case series. 2017 , 9, 1253-1260	6

707	Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus. 2014 , 5, 27-39	8
706	Increase in colonic diverticular hemorrhage and confounding factors. 2016 , 7, 440-6	17
705	Endovascular treatment of extracranial vertebral artery stenosis. 2012 , 4, 391-400	23
704	Positive influence of aspirin on coronary endothelial function: Importance of the dose. 2013 , 5, 426-33	1
703	Impairment of aspirin antiplatelet effects by non-opioid analgesic medication. 2015 , 7, 383-91	13
702	Alternative Mechanism of Aspirin in Anti-Thrombotic Therapy: Inhibition of Thrombin Activatable Fibrinolysis Inhibitor. 2012 , 33, 3048-3054	2
701	Should aspirin be stopped before carpal tunnel surgery? A prospective study. 2013 , 4, 299-302	4
700	Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. 2012 , 19, 1142-53	6
699	Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012. 2013 , 20, 603-15	36
698	Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. 2020 , 27, 809-907	16
697	Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. 2015 , 7, e28099	14
696	Effect of Long-Term, Low-Dose Aspirin Therapy on Renal Graft Function. 2017 , 15, 400-404	3
695	Antithrombotic Treatment for Symptomatic Peripheral Artery Disease. 2019 , 35, 557-562	2
694	Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. 2020 , 9,	2
693	Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease. 2008 , 12, 4-11	16
692	A Brief Overview of Medical Management Options in Peripheral Arterial Disease.	
691	Flow cytometric analysis of platelet function to detect high on-treatment residual platelet reactivity in patients on dual antiplatelet therapy. 2021 ,	
690	A protocol for DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease. 2021 , 2, e0163	0

689	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. 2021 , 21, 218	0
688	Antiplatelet therapy in stroke prevention after non-cardioembolic transient ischemic attack. 2021 , 13, 14-19	1
687	Effect of Preoperative Continuation of Aspirin on Postoperative Bleeding After Off-Pump Coronary Artery Bypass Graft: A Prospective Cohort Study. 2021 , 13, e18697	
686	Anticoagulants for acute ischaemic stroke. 2021 , 10, CD000024	3
685	Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients. 2021 , 21, 409	1
684	The role of platelets in the pathogenesis of atherosclerosis. 2021 , 17, 106-119	
683	Medical Management of Peripheral Artery Disease. 2021 , 39, 471-482	0
682	?????????????????. 2002 , 13, 141-150	1
681	Cerebrovascular Disease. 2003 , 129-149	
680	Antikoagulantien und Thrombozytenaggregationshemmer. 2003 , 220-232	
679	Antithrombotic Trialists Collaboration ? meta-analysis. 2003 , 14, 44-47	1
678	The Newer Coronary Risk Factors. 2003 , 193-211	
677	Arterial Occlusive Diseases of the Extremities. 2003 , 47-79	
676	Prevention of Stroke. 2003 , 349-362	
675	Renal Artery Disease. 2003 , 81-109	
674	Peripheral Vascular Disease in Diabetes.	
673	Antikoagulantien und Thrombozytenaggregationshemmer. 2004 , 356-368	
672	Fibrinolytika. 2004 , 911-926	

671 Neurologie und Psychiatrie. **2004**, 299-331

670 Herzchirurgische Intensivmedizin. **2004**, 1077-1098

669 Durchblutungsfördernde Mittel. **2004**, 554-563

668 Durchblutungsfördernde Mittel. **2004**, 480-489

667 Antikoagulantien und Thrombozytenaggregationshemmer. **2004**, 265-278

666 Prävention der koronaren Herzerkrankung. **2004**, 1119-1147

665 Anticoagulants/Antithrombotic Therapy. **2004**, 831-842

664 ????????????????? Atherothrombosis???,????????????????????2004, 15, 510-516

1

663 Current use of antiplatelet agents. **2004**, 27-55

662 The Role of P2Y12 Blockade in Acute Coronary Syndromes and in the Catheterization Laboratory. **2004**, 411-434

661 Statins and Plaque Stabilization. **2004**, 521-562

660 Detection and management of aspirin resistance. **2004**, 3, 177-83

o

659 Treatment of Vulnerable Plaques. **2004**, 164-202

658 Traitement Antithrombotique des Syndromes Coronariens aigus sans Sus-décalage de ST. **2005**, 189, 217-226

657 The kaiser permanente northwest cardiovascular risk factor management program: a model for all. **2005**, 9, 19-26

656 Periphere arterielle Verschlusskrankheit. **2005**, 26,

655 Coagulation, thrombosis, and coronary heart disease. **2005**, 466-479

654 Chronic infection and circulating markers of inflammation. **2005**, 448-465

653 Antiplatelet therapy. **2005**, 21-45

652 Antithrombotic Therapy for Carotid Artery Stenosis. **2005**, 111-122

651 Stroke Prevention, Blood Cholesterol and Statins. **2005**, 123-150

650 Aspirin and Cardiovascular Disease Prevention in Women: New Findings from the Women's Health Study. **2005**, 1, 9-10

649 Antithrombotic Therapy for Carotid Artery Stenosis. **2005**, 135-146

648 Ximelagatran, the Oral Anticoagulant of the Future An Evidence Based Review. **2005**, 2005,

647 Medical Treatment of Peripheral Arterial Disease. **2006**, 271-292

646 Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance. **2006**, 85-92

645 Is er een verschil tussen de diverse soorten acetylsalicylzuur en hun toedieningsvormen? Is er een optimaal tijdstip van innemen?. **2006**, 75-76

644 Arteriopatī coronaria crītica. **2006**, 74-83

643 Measures of Platelet Activation and Aggregation. **2006**, 467-485

642 Is it Possible to Screen Patients for Aspirin Resistance Using 11-dehydro-Thromboxane B2 Spot Urine Levels?. **2006**, 32, 1242-1247

641 Tserebrovaskulyarnye zabolvaniya i sakharnyy diabet 2 tipa. **2006**, 9, 34-40

1

640 Issues in acute management. **2006**, 41-46

639 Anticoagulation and Antiplatelet Agents. **2006**, 501-524

638 Peripheral Arterial Disease. **2006**, 585-610

637 Optimal antiplatelet and anticoagulation therapy, prevention and management of thrombotic complications. **2006**, 39-52

636 Gerinnungsphysiologische Voraussetzungen. **2007**, 69-79

635 Aging and the Cardiovascular System. **2007**, 2439-2451

634 Chronic Stable Angina. **2007**, 290-313

633 Peripheral Arterial Disease. **2007**, 379-388

1

632 Genetic aspects on the effects of anticoagulant and antiplatelet drugs. **2007**, 29, 721-725

631 Hemostatic Aspects of Cardiovascular Medicine. **2007**, 339-369

630 Peripheral Vascular Disease. **2007**, 309-321

629 Cerebrovascular Disease in Hypertension. **2007**, 392-405

628 Prevention Guidelines: Management of the Coronary Patient. **2007**, 26-29

627 Anti-thrombotic therapy for metabolic syndrome. **2007**, 18, 607-613

626 Revascularization Options for Ischemic Heart Disease: Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention. **2007**, 157-177

625 Erkrankungen der hirnversorgenden Arterien. **2007**, E6.1-E6.5

624 Carotid Artery Intervention. **2007**, 1741-1753

623 Antithrombotic Therapy in Hypertension. **2007**, 1101-1104

622 Meta-analyses of Hypertension Trials. **2007**, 316-324

621 ST-Elevation Myocardial Infarction. **2007**, 246-289

620 Antiplatelet drugs for polycythemia vera and essential thrombocythaemia.

619 Part II. Specific Complications by Vessel Area or Specific Scenarios. **2007**, 61-62

618 Resistance to antiplatelet drugs. **2007**, 139-154

- 617 [Cardiovascular prevention with peripheral artery disease]. **2007**, 148, 1303-9
- 616 Angina, its diagnosis and treatment.. **2007**, 49, 334-340
- 615 Chuanxiong type compounds for preventing cardiovascular diseases.
- 614 What to do When there is no Evidence. 11-14 2
- 613 Acute Stroke Manatement and Prevention of Recurrences. 113-126
- 612 CORONARY RISK FACTORS. **2008**, 1-27
- 611 Antikoagulantien und Thrombozytenaggregationshemmer. **2008**, 379-393
- 610 Antiplatelets and Anticoagulation in the Setting of Acute Heart Failure Syndrome. **2008**, 639-652
- 609 Monitoring of anti-platelet therapy and anti-platelet drug resistance. **2008**, 30, 953-959 1
- 608 Medicamenteuze preventie en behandeling van atherotrombose. **2008**, 89-101
- 607 Durchblutungsffördernde Mittel. **2008**, 567-574
- 606 Prevalence and Clinical Characteristics of Aspirin Resistance in the Patients with Type 2 Diabetes. **2008**, 32, 171
- 605 THE PATIENT WITH CHEST PAIN. **2008**, 117-187
- 604 [Clinical features and treatments of antiphospholipid syndrome]. **2008**, 31, 152-8 1
- 603 Antithrombotic therapy in heart disease. **2008**, 19, 8-11
- 602 Traitement de l'angor stable et des syndromes coronariens aigus sans sus-décalage du segment ST. **2008**, 73-100
- 601 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2008**, 127-155
- 600 21 Het acute myocardinfarct met ST-elevatie op het ECG. **2008**, 183-192

- 599 22 Instabiele angina pectoris en myocardinfarct zonder ST-elevatie op het ECG. **2008**, 193-196
- 598 Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. **2008**, 1009-1033 ₁
- 597 ATHEROSCLEROSIS AND THROMBOSIS IN DIABETES MELLITUS: NEW ASPECTS OF PATHOGENESIS. **2008**, 89-113 ₀
- 596 Antiplatelet agents for ischemic stroke: current status and future directions. **2008**, 30, 834-840
- 595 Clinical practice of antiplatelet therapy. **2008**, 19, 179-182 ₁
- 594 Medical management of stable angina. **2008**, 2008,
- 593 Management of Peripheral Arterial Disease in the Elderly. **2008**, 749-768
- 592 Antiplatelet Agents. **2008**, 176-194
- 591 Emerging oral antiplatelet receptor inhibitors. **2008**, 119-126
- 590 Pharmacological treatment in peripheral arterial disease. **2008**, 811-821
- 589 NHG-Standaard CVA. **2009**, 383-401
- 588 Medical Therapy in Patients Managed in a Chest Pain Observation Unit. **2009**, 147-153
- 587 Which Therapy for Which Condition?. **2009**, 388-458
- 586 CORONARY ARTERY DISEASE. **2009**, 321-365
- 585 1. Molecular Mechanisms and Characteristics of Antiplatelet Drugs. **2009**, 40, 253-260 ₁
- 584 STROKE. **2009**, 743-752
- 583 Chapter 17 Antithrombotic therapy in hypertension. **2009**,
- 582 Acute Coronary Syndromes. **2009**, 680-691

563 Antithrombotic Therapy in Carotid and Peripheral Intervention. **2010**, 283-305

562 Thienopyridines in Stable Coronary Disease. **2010**, 131-141

561 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion. **2010**, 389-403

560 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes. **2010**, 203-215

559 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction. **2010**, 219-233

558 Clinical Pharmacology of Cardiovascular Drugs. **2009**, 367-402

557 Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction. **2010**, 145-163

556 Antithrombotic Therapy in Percutaneous Coronary Intervention. **2010**, 261-282

555 Aterotrombóza: antiagregatívák. **2009**, 51, 19-21

1

554 Cerebrovascular Disease. **2010**, 1424-1442

553 Lower Extremity Arterial Disease. **2010**, 1576-1592

2

552 Athérosclérose. **2010**, 287-491

551 Thérapeutique des déficiences associées. **2010**, 175-189

550 Fibrinolytika. **2010**, 801-812

549 Prévention des récurrences d'accident vasculaire cérébral. **2010**, 19-25

548 Durchblutungsfördernde Mittel. **2010**, 589-596

547 SALICYLATES, PARACETAMOL, AND OTHER NON-OPIOID ANALGESICS. **2010**, 165-221

546 Carotid Artery Disease. **2010**, 1443-1468

545 Antithrombotic Agents. **2010**, 541-555

544 Chronic Coronary Artery Disease. **2010**, 97-105

543 Atheromatous Embolization. **2010**, 2422-2434

542 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2010**, 250-262

541 The Ethics of Prescribing Medications to Older People. **2010**, 29-42

540 Manejo de los antiagregantes en el perioperatorio. **2010**, 123-140

539 Treatment of Left Ventricular Failure. 152-160

538 Oral Antiplatelet Therapy. **2010**, 73-82

537 Special Management of Diabetic Patients with STEMI. **2010**, 183-196

536 Cardiology. 185-193

535 Diagnosis and Management of Ischemic Stroke. **2011**, 373-390

1

534 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225

533 Pharmacological Prerequisites for Treatment of Complex Patients with Peripheral Artery Disease. **2010**, 10-21

532 Peripheral Arterial Disease. **2011**, 311-323

531 Cerebrovascular Disease. 698-709

1

530 Acute Coronary Syndromes and Myocardial Infarction. 234-255

529 Macrovascular Disease in Diabetes. 152-160

528 Newer Coronary Risk Factors. **2011**, 113-139

527 Risk Reduction in the Diabetic Patient. **2011**, 281-315

1

526 Antithrombotic therapy: what the dental surgeon has to know. **2010**, 1, 92-98

525 Clopidogrel and Salicylates. **2011**, 139-153

524 Measuring of platelet activity and efficacy of antiplatelet therapy. **2010**, 52, 15-20

523 Oral antiplatelet therapy. **2011**, 311-319

522 NHG-Standaard CVA. **2011**, 439-457

521 Durchblutungsfördernde Mittel. **2011**, 607-614

520 Management of ST-elevation myocardial infarction. **2011**, 474-484

519 Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. **2011**, 971-991

518 Diabetes Mellitus. **2011**, 731-755

517 Akutes Koronarsyndrom, Myokardinfarkt, instabile Angina pectoris. **2011**, 411-431

516 Peripheral Arterial Disease Assessment and Management. **2011**, 512-525

515 Prevention of Ischemic Heart Disease in Women. **2011**, 398-414

514 Atheroembolization. **2011**, 1483-1488

513 Kardiovaskuläre Erkrankungen. **2011**, 1-186

512 Antiplatelet Therapy. **2011**, 69-85

511 Inflammation and Immunity as Targets for Drug Therapy in Acute Coronary Syndrome. **2011**, 271-288

510 The Difference in Aspirin Resistance Based on an Optical Platelet Aggregometer and the PFA-100 in Patients with Acute Ischemic Stroke. **2011**, 13, 114

509 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2011**, 341-359

508 NHG-Standaard TIA. **2011**, 537-552

507 Management of the postcoronary patient. **2011**, 650-659

506 Fibrinolytic therapy. **2011**, 289-297

505 Antiplatelet Therapy. **2011**, 201-221

504 Nonresponsiveness to Antiplatelet Therapy. **2011**, 222-231

503 Antithrombotic therapy in secondary prevention. **2011**, 30, 224-233

502 Vasculäre Erkrankungen. **2011**, 1055-1195

501 Akute zerebrale Erkrankungen. **2011**, 363-390

500 Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy. **2011**, 313-321

499 Diabetes and Cardiovascular Disease. **2011**, 345-370

498 Stroke prevention in atrial fibrillation. **2011**, 2011,

497 Intracranial Vertebral Artery Stenting. 427-435

496 Identifying opportunities for a medical group to improve outcomes for patients with coronary artery disease and heart failure: an exploratory study. **2011**, 15, 4-14

2

495 Compliance as the major effectiveness determinant in preventive acetylsalicylic acid therapy. **2011**, 10, 102-109

494 Prognostic Implications of Depression in Ischemic Syndromes. **2012**, 147-167

493 Antithrombotics for Ischemic Stroke. 205-222

492 Secondary Prevention Strategies. **2012**, 169-182

491 Lower Extremity Intervention. **2012**, 19-39

490 Aspirin in Neurology. **2011**, 2011, 1-9

489 Coronary Plaque Rupture in Patients with Acute. **2011**, 49-67

488 Thrombolytic Intervention. **2012**, 142-158

487 Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes. **2012**, 223-236

486 Durchblutungs- und Edernde Mittel. **2012**, 613-620

485 Innovations in Stroke Clinical Trial Design. **2012**, 911-916

484 Peripheral Vascular Disease. **2012**, 237-246.e3

483 Peripheral Artery Diseases. **2012**, 1338-1358

1

482 Antiplatelet Therapy for Secondary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke. **2012**, 14, 1

1

481 A Stepped Care Approach to the Management of Chronic Kidney Disease. **2012**, 2205-2239

1

480 Systemic Thromboembolism in Pregnancy: Thromboprophylaxis. **2012**, 31-50

479 Antithrombotic therapies. **2012**, 44-66

478 Treatment algorithm in patients with stable angina. **2012**, 312-330

477 Clinical perspectives on the management of advanced stable coronary disease. **2012**, 377-384

476 Aspirin. 12-25

475 Stroke: Thrombolysis and Antithrombotic Therapy. 272-284

474 Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies. 285-305

- 473 Antithrombotic Therapy in NonST-Segment Elevation Acute Coronary Syndromes. 213-235
- 472 Management of Chronic Coronary Artery Disease. 60-85
- 471 Medical Management of Carotid Artery Disease. 389-404
- 470 Acute coronary syndromes. **2012**, 34-57
- 469 TIA oder Aura [Wie sicher ist die Diagnose?]. **2012**, 23, 46-51
- 468 Venous Thromboembolism. 366-375
- 467 Antithrombotic therapy for atherothrombotic disease. **2013**, 24, 30-37
- 466 Management of thrombotic risk in old patients. **2013**, 24, 45-52
- 465 Durchblutungsfördernde Mittel. **2013**, 601-607
- 464 Cerebrovascular Disease in Hypertension. **2013**, 303-312
- 463 Study on Risk of Gastrointestinal Complications in Low-dose Aspirin Therapy Using the National Receipt Database. **2013**, 39, 471-481 3
- 462 Peripheral Arterial Disease. **2013**, 781-796
- 461 Pre-procedural Considerations. **2013**, 27-43 1
- 460 Secondary Arterial Reconstruction. **2013**, 1-23
- 459 A Study of Coronary Heart Disease in Postmenopausal Women and Identification of Major Modifiable Determinant Risks for its Prevention. **2013**, 1, 56-62
- 458 Agents antiplaquettaires et athérotrombose. **2013**, 197, 375-388
- 457 Oral anticoagulants for the secondary prevention of coronary heart disease.
- 456 Ischemic Stroke. 35-72

455 Medical therapy for peripheral vascular disease. **2013**, 48-59

454 Prognosis following myocardial infarction. **2013**, 116-133

453 American Versus European Guidelines: Critical Appraisal. **2014**, 139-184

452 Secondary Prevention Within the Community. 205-225

451 Antiplatelet Therapy. New Potent P2Y12 Inhibitors. **2014**, 31-57

450 PCI Considerations in Women: Gender-Specific Outcomes and Challenges. **2014**, 227-241

449 Adjunctive Pharmacology for Coronary Intervention. **2014**, 143-156

448 Managing Anticoagulation in Patients with Mechanical Valves. **2014**, 525-535

447 Acute Coronary Syndromes. **2014**, 15-36

1

446 Pharmacotherapy Considerations in Cardiovascular Disease in Women: Therapeutic Implications for Cardiovascular Disease. **2014**, 427-447

445 Management of Stable Ischemic Heart Disease in Women. **2014**, 83-111

444 Chronic Stable Angina. **2014**, 117-123

443 Aspirin as Primary Prevention of Acute Coronary Heart Disease Events. **2014**, 4, 5357-5367

442 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2014**, 265-275

441 Pharmacological Secondary Prevention of Ischemic Stroke. **2014**, 7, 76

1

440 Vascular Complications of Diabetes Mellitus. **2014**, 1-65

439 Progress of antiplatelet therapy. **2014**, 36, 210-215

438 Diseases of Renal Macrocirculation: Atherosclerosis and Renal Artery Stenosis. **2014**, 1-26

- 437 Medical Management of Coronary Artery Disease. **2014**, 1-17
- 436 Risk Factor Analysis for Incidence of Major Adverse Cardiac Events after Percutaneous Coronary Intervention Treatment. **2014**, 40, 278-284
- 435 Management of Peripheral Arterial Disease. 267-305
- 434 Thrombosis in Diabetes and Its Clinical Management. 185-214
- 433 Spontaneous Early Recanalization after Acute Innominate Artery Thromboembolic Occlusion Secondary to Abrupt Aspirin and Statin Discontinuation: A Case Report. **2014**, 63, 532-5 2
- 432 Antiplatelet Therapy in Patients with Coronary Stent Undergoing Orthopedic Surgery: Is It Still No Man's Land?. **2015**, 41-49
- 431 PAD and Claudication. **2015**, 85-100
- 430 Critical Limb Ischemia. **2015**, 101-118
- 429 Antiplatelet Agents. **2015**, 133-137 1
- 428 Medical Management of a Stroke. **2015**, 137-149 1
- 427 Knowledge of Cardiovascular Medications in a Culturally Diverse Elderly Community. **2014**, 2, 118-128
- 426 Akutes Koronarsyndrom, Myokardinfarkt, instabile Angina pectoris. **2015**, 671-694
- 425 Intensivtherapie bei akutem Koronarsyndrom, Myokardinfarkt und instabiler Angina pectoris. **2015**, 1-40
- 424 Medical Management of Coronary Artery Disease. **2015**, 2369-2382
- 423 An Overview of Treatment and Guidelines: ESC/ACC-AHA/NICE. **2015**, 33-56
- 422 Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. **2015**, 6, 267-277 0
- 421 Atherosclerotic Peripheral Artery Disease: Clinical Management. **2015**, 2983-3006
- 420 Gestion pñti-opñtatoire des patients traitñs par antithrombotiques en chirurgie orale. Argumentaire. **2015**, 21, S15-S81 1

- 419 Principles of Primary and Secondary Prevention of Cardiovascular Disease. **2015**, 1627-1664
- 418 Diseases of Renal Macrocirculation: Atherosclerosis and Renal Artery Stenosis. **2015**, 3715-3737
- 417 Secondary Arterial Reconstructions. **2015**, 3321-3339
- 416 Systemic Thromboembolism in Pregnancy: Thromboprophylaxis. **2015**, 59-79
- 415 The unity of approaches to preventing coronary heart disease and cerebrovascular diseases. **2015**, 18, 24 1
- 414 DMSO Clinical Pharmacology. **2015**, 49-80
- 413 Platelets. 187-195
- 412 Acetylsalicylic acid therapy in patients undergoing planned surgery. **2015**, 6, 48-57
- 411 Acetylsalicylic acid in the treatment of cardiovascular diseases. **2015**, 6, 17-21
- 410 IS THE PRACTICE OF DISCONTINUING ASPIRIN THERAPY PRIOR TO DENTAL EXTRACTION CORRECT? A REVIEW. **2015**, 4, 16779-16785
- 409 [Antithrombotic treatment as primary and secondary prevention of stroke]. **2016**, 116, 85-88 0
- 408 Heterogeneous Causes of Stroke: Antithrombotics. **2016**, 99-104
- 407 [The modern principles of management of intermittent claudication]. **2016**, 77-87 0
- 406 Secondary Arterial Reconstruction. **2016**, 1-22
- 405 S.A.M. and Breast Cancer Focus on Aspirin and Other Integrative Aspirin-Like Medicines: The Real Natural Options. **2016**, 173-194
- 404 Stable Ischemic Heart Disease. **2016**, 1-70
- 403 Role of Antiplatelet Therapy in Neurosurgery: Efficacy and Safety Profiles. **2016**, 65-89
- 402 Management of Angina. **2016**, 111-163

- 401 Peri- and Post-procedural Antithrombotic Therapy in Women. **2017**, 73-100 0
- 400 OBSOLETE: Cardiovascular Disease Prevention. **2017**,
- 399 The association between aspirin resistance and extent and severity of coronary atherosclerosis. **2018**, 5, 323-328 2
- 398 Optimal medical therapy to improve saphenous vein graft patency. **2017**, 23, 196-203
- 397 Perioperative Cardioprotective Strategies in Noncardiac Surgery. **2017**, 749-761
- 396 Platelets in Acute Coronary Syndromes. **2017**, 1015-1028
- 395 Antiplatelet Therapy in Patients with Coronary Artery Disease. **2017**, 1361-1371
- 394 Antiplatelet Therapy in Peripheral Artery Disease. **2017**, 1381-1390
- 393 Stroke Pharmacogenetics. **2017**, 327-410
- 392 Overview of Peripheral Arterial Disease of the Lower Extremity. **2017**, 291-318
- 391 The comparison of the effects of the cilostazol on the stiffness parameters in different arterial systems in the patients with peripheral arterial disease. 11-11
- 390 Antimalarial and Other Antiparasitic Drugs. **2017**, 623-652
- 389 Stable Ischemic Heart Disease. **2017**,
- 388 ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE (REVIEW OF LITERATURE). **2017**, 2, 109-113 1
- 387 Modern principles of antiplatelet antithrombotic therapy. **2017**, 95, 586-593
- 386 Adjunctive pharmacotherapy and coronary intervention. **2017**, 137-153
- 385 Inhibitory Effects of Total Saponin Korean Red Ginseng on Thromboxane A₂ Production and P-Selectin Expression via Suppressing Mitogen-Activated Protein Kinases. **2017**, 23, 310-320 1
- 384 Tomato Concentrates Inhibit Platelet Function and Thrombus Formation in Rats. **2017**, 17, 25-33

383 PERIOPERATIVE BLEEDING IN AN UROLOGICAL PATIENT ON ASPIRIN THERAPY. **2017**, 56, 83-89

382 Basic principles of antiplatelet therapy from the perspective of new recommendations. **2017**, 8, 26-35

381 OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management. **2018**,

380 Zerebrale Mikroangiopathie. **2018**, 1-4

379 Percutaneous Coronary Intervention: Special Considerations in Women. **2018**, 275-289

378 Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Is Less More?. **2018**, 12, 91

377 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2018**, 99-122.e3

376 Primärprävention und Sekundärprävention des Hirninfarkts. **2018**, 1-31

375 Effect of Sociodemographic Variables and Other Factors on the Usage of Different Doses of Aspirin in Postmyocardial Infarction Patients: A Cross-sectional Study. **2018**, 19, 49-53

374 Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. **2018**, 291-303

373 Ischemic Stroke. **2018**, 827-918

372 Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients. **2019**, 112, 138-146

1

371 Recent advances in the pharmacotherapy of cardiovascular diseases. **2018**, 17, 108-112

370 Neurology. **2018**, 271-306

369 The experience of using acetylsalicylic acid in a comorbid patient with cad and type 2 diabetes. **2018**, 54-60

368 Antiplatelet Therapy in Cardiovascular Disease. **2019**, 195-207

367 The effect of prior administration of oral dipyridamole on cerebral blood flow and blood pressure of SD rats during global cerebral ischemia. **2018**, 241-245

366 Effect of Tea Dregs Form and Different Fermentation Process on the Nutrient, Tannin, Saponin, flavonoid content and Antioxidant Activity. **2018**, 18, 25-33

- 365 ASPIRINA NA PREVENÇÃO PRIMÁRIA DE EVENTOS CARDIOVASCULARES EM PACIENTES DIABÉTICOS: UMA REVISÃO. **2019**, 10, 13-22
- 364 Sporadic cerebral non-amyloid microangiopathy: pathogenesis, diagnosis, and features of treatment policy. **2018**, 10, 13-22 5
- 363 Intervención coronaria en pacientes con fibrilación auricular. **2019**, 18, 15-20
- 362 Fascia Iliaca Block as an Anesthetic Technique for: Acute Lower Limb Ischemia. **2019**, 13, 547-553
- 361 Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. **2019**, 377-390
- 360 [Oxidative stress and inflammation as links in a chain in patients with chronic cerebrovascular diseases]. **2019**, 119, 106-114 2
- 359 Encyclopedia of Behavioral Medicine. **2019**, 1-2
- 358 Benefits of a combination of clopidogrel and aspirin in patients with high cardiovascular risk. **2019**, 12, 504
- 357 Thérapeutique des troubles associés. **2019**, 253-267
- 356 Drug-Coated Balloon and Antithrombotic Therapy. **2019**, 209-218
- 355 Primärprävention und Sekundärprävention des Hirninfarkts. **2019**, 1-31
- 354 Dynamics of course and adherence to treatment in conservative and surgical treatment of chronic coronary artery disease connected with hypertension. **2019**, 1, 34-38
- 353 Preventie. **2019**, 175-194
- 352 Antiplatelet agent plus small dose of anticoagulant for atherosclerotic vascular diseases—COMPASS trial. **2019**, 30, 815-827
- 351 Management of Aortic Atherothrombi. **2019**, 427-433
- 350 High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-ST Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. **2019**, 113, 357-363 0
- 349 High Residual Platelet Activity in Response to Acetylsalicylic Acid in Acute Coronary Syndrome: A New Challenge for Antiplatelet Treatment?. **2019**, 113, 364-366 1
- 348 Colorectal Cancer Prevention. **2019**, 473-509 1

- 347 Seleccion de lo mejor del a 2018 en riesgo vascular y rehabilitaci cardiaca. **2019**, 54, 44-50
- 346 [Therapeutic Strategies in Patients with Stable Coronary Artery Disease: The Role of Coronary Revascularization]. **2019**, 108, 401-409 1
- 345 Comprehensive Risk Management Chart for Cerebro-cardiovascular Disease 2019. **2019**, 108, 1024-1074 0
- 344 Current Medical and Surgical Stroke Prevention Therapies for Patients with Carotid Artery Stenosis. **2019**, 16, 96-103 1
- 343 Akut Koroner Sendrom ile Ba ıran Hastalarda Asetil Salisilik Asit Direncinin Ara ı ımas ı -
- 342 Motor function recovery in patients after ischemic stroke. **2019**, 11, 89-94
- 341 Designing a text messaging program to increase adherence to medication for the secondary prevention of cardiovascular disease. 0
- 340 The dilemma of aspirin resistance in obese patients. **2019**, 7, 404 5
- 339 Clinical use of low-dose aspirin for elders and sensitive subjects. **2019**, 7, 3168-3174 0
- 338 Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; ı Randomised Clinical Trial. **2019**, 17, 635-643 0
- 337 Consensus Report on Patient Blood Management in Cardiac Surgery by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Cardiology (TSC), and Society of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care (SCTAIC). **2019**, 27, 429-450 2
- 336 Hemostasis in Cardiac Surgery: How We Do it with Limited Resources.
- 335 Effect of Continuation of Antiplatelet Therapy on Survival in Patients Receiving Physician Home Visits.
- 334 Large-scale randomized evidence: Trials and meta-analyses of trials. **2020**, 51-66
- 333 Antithrombotika und Antih ıorrhagika. **2020**, 395-420
- 332 Revascularization: Femoropopliteal. **2020**, 111-124.e3
- 331 Emerging clinical setting of direct oral anticoagulants: atherothrombotic events prevention. **2020**, 21, 1-5
- 330 Associations of antithrombotic agent use with clinical outcomes in critically ill patients with troponin I elevation in the absence of acute coronary syndrome. **2020**, 15, e0233178

- 329 [Gastrointestinal Bleeding in Patients with Coronary Heart Disease: Preventive Options]. **2020**, 60, 125-135
- 328 Secondary prevention after acute coronary syndrome. **2020**, 66, 236-241
- 327 Cognitive impairment and distal polyneuropathy in a patient with diabetes mellitus in neurological outpatient practice. **2020**, 12, 111-116
- 326 Stroke Disease Prediction based on Deep Learning using the Elderly Cohort DB. **2020**, 21, 1191-1200 2
- 325 Adverse reactions with the use of non-steroidal anti-inflammatory drugs. **2020**, 35-50
- 324 CURRENT TRENDS IN CRITICAL LIMB ISCHEMIA - REVIEW. **2020**, 1-3
- 323 Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. **2021**, 208, 92-98 0
- 322 Evaluation of Provider Implementation of the 2019 American College of Cardiology and American Heart Association Aspirin for Primary Prevention Guideline Recommendations for Older People. **2021**, 36, 573-579
- 321 Outpatient Management of Patients With Angina With No Obstructive Coronary Arteries: How to Come to a Proper Diagnosis and Therapy. **2021**, 8, 716319 1
- 320 Safety and Efficacy of Combined Low-Dose Lithium and Low-Dose Aspirin: A Pharmacological and Behavioral Proof-of-Concept Study in Rats. **2021**, 13, 1 1
- 319 Effect of Continuation of Antiplatelet Therapy on Survival in Patients Receiving Physician Home Visits.
- 318 Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data. **2020**, 20, 1145 1
- 317 Effect of Aspirin Consumption on Hematuria and Cardiovascular Complications After Transurethral Resection of Prostate. **2020**, 18,
- 316 Aspirin use in elderly for primary prevention of Cardiovascular Disease: Double edged. **2020**, 50, 403-404
- 315 Antiplatelet Therapy. **2021**, 249-288
- 314 Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. **2020**, 26, 5953-5968 0
- 313 Management of patients with neurological complications of diabetes mellitus. **2020**, 114-119
- 312 Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. **2021**, 23, 352-362 0

- 311 Independent Impact of Peripheral Artery Disease on Percutaneous Coronary Intervention. **2020**, 9, e017655 2
- 310 [Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy]. **2020**, 76, 282-296
- 309 Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey. **2020**, 8, E41-E47 0
- 308 ACETYLSALICYLIC ACID RESISTANCE: RISK FACTORS, MECHANISMS, DIAGNOSTIC TESTS. **2020**, 6, 16-34 0
- 307 Ischemic stroke and antithrombotic therapy: key aspects. **2019**, 10-17 1
- 306 Encyclopedia of Behavioral Medicine. **2020**, 157-158
- 305 Diabetes mellitus and muscle infarction. **2020**, 275-283
- 304 [Expanding the possibilities of antithrombotic therapy of cerebrovascular pathology]. **2020**, 120, 123-128 0
- 303 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 302 Zerebrale Mikroangiopathie. **2020**, 845-848
- 301 Zerebrovaskuläre Erkrankungen. **2020**, 1-25
- 300 ERKRANKUNGEN DER GEFÄSSE. **2020**, E-1-E17-4
- 299 Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target. **2020**, 233-261
- 298 Acute ST Elevation Myocardial Infarction. **2020**, 111-123
- 297 Primärprävention und Sekundärprävention des Hirninfarkts. **2020**, 883-913
- 296 Management of patients with acute respiratory infections and chronic cardiovascular pathology. Clinical guidelines 2020. **2020**, 45-85 1
- 295 Evaluating the effectiveness of a support programme for people with type 2 diabetes mellitus in primary care: an observational prospective study in Ecuador. **2020**, 4,
- 294 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. **2021**, 338, 55-63 0

- 293 Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. **2021**, 5
- 292 Excess Mortality in Aspirin and Dipyron (Metamizole) Co-Medicated in Patients With Cardiovascular Disease: A Nationwide Study. **2021**, 10, e022299 1
- 291 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. **2021**, 50, 401-411 4
- 290 Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease. **2021**, 22, 7
- 289 Beta-blockers in patients without heart failure after myocardial infarction. **2021**, 11, CD012565 1
- 288 Gastrointestinal Bleeding in Antithrombotic Therapy in Patients with Coronary Heart Disease: Risk Factors, Pathogenesis and Treatment. **2020**, 30, 14-23 0
- 287 Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. **2007**, 32, 97-109
- 286 Venous and Arterial Thrombosis Is There a Link?. **2015**,
- 285 Antikoagulantien und Thrombozytenaggregationshemmer. 429-442
- 284 Durchblutungsfördernde Mittel. 623-631
- 283 Therapie mit Antikoagulanzen, PII-Enzymfunktionshemmern und Thrombolytika. **2004**, 115-131
- 282 Cardiovascular Cerebrovascular Diseases Diabetes Mellitus: Co-morbidities that Affect Dental Care for the Older Patient. **2008**, 157-189
- 281 Antiplatelet Drugs. **2005**, 203-218
- 280 Peripheral Arterial Disease. **2005**, 807-828
- 279 Aspirin and Antiplatelet Agents in the Prevention of Complications of Coronary Artery Disease. **2006**, 285-307
- 278 Antiplatelet Therapy. **2008**, 19-23
- 277 Current State of Medical Therapies for Peripheral Vascular Disease. **2008**, 139-149
- 276 Platelets and new antiplatelet drugs. **2005**, 2, 465-502

275	Stellenwert der frühzeitigen Diagnostik und Behandlung der Peripheren Arteriellen Verschlusskrankheit für die Prävention kardiovaskulärer Ereignisse. 2008 , 787-805	
274	Secondary prevention in minor ischemic stroke with antiplatelet treatment. Systematic review and meta-analysis of comparative studies with aspirin under non-inferiority criteria. 2020 , 61, 265-282	
273	Sekundärprophylaxe der zerebralen Ischämie. 2020 , 39, 644-650	
272	[Decreasing cardiovascular morbidity: how to improve adherence to the treatment in the translational era]. 2020 , 92, 49-53	
271	Platelet Apoptotic Response May Be Associated With the Capacity of Aspirin to Inhibit Platelets. 2020 , 76, 584-591	
270	Clinical impacts of cerebral microbleeds in patients with established coronary artery disease. 2021 , 39, 259-265	1
269	Acute Coronary Syndrome. 2021 , 59-80	
268	Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy. 2020 , 53, 663-677	0
267	The double-edged sword of COX-2 selective NSAIDs. 2002 , 167, 1131-7	47
266	Antiplatelet therapy and atherosclerotic events. Commentary is inaccurate. 2002 , 324, 917	1
265	Management of patients with suspected angina, but without known myocardial infarction: a cross-sectional survey. 2004 , 54, 429-33	7
264	Management of carotid artery stenosis. Update for family physicians. 2005 , 51, 984-9	8
263	Preventing recurrent ulcer bleeding. Switch from acetylsalicylic acid to clopidogrel or add esomeprazole?. 2006 , 52, 455-7	0
262	NSAID hysteria--Chicken Little revisited. 2005 , 7, 13	
261	Aspirin resistance and its implications in clinical practice. 2005 , 7, 76	1
260	The discovery of aspirin's antithrombotic effects. 2007 , 34, 179-86	63
259	Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. 2007 , 53, 1177-84	15
258	A review of picotamide in the reduction of cardiovascular events in diabetic patients. 2007 , 3, 93-8	21

257	Peripheral arterial disease and ankle-brachial pressure index as predictors of mortality in residents of Metlika County, Slovenia. 2006 , 47, 327-34	7
256	Risk reduction with clopidogrel in the management of peripheral arterial disease. 2007 , 3, 289-97	10
255	Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. 2007 , 3, 1019-27	18
254	Aspirin and clopidogrel response variability: review of the published literature. 2008 , 35, 313-20	24
253	Antiplatelet therapy in populations at high risk of atherothrombosis. 2006 , 98, 711-21	9
252	Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. 2006 , 98, 1126-35	4
251	Medical management and cardiovascular risk reduction in peripheral arterial disease. 2008 , 13, 113-9	7
250	Update on the Canadian Diabetes Association 2008 clinical practice guidelines. 2009 , 55, 39-43	38
249	Secondary prevention of atherothrombotic events after ischemic stroke. 2009 , 84, 43-51	7
248	Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. 2009 , 84, 149-60	4
247	Regular use of traditional analgesics predicts major coronary events: A cohort study. 2009 , 5, 9-15	1
246	Stroke Best Practices: a team approach to evidence-based care. 2004 , 96, 5S-20S	2
245	Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. 2009 , 10, 163-75	3
244	Pharmacogenetics of cardiovascular drug therapy. 2009 , 6, 55-65	6
243	Antiplatelet Resistance-Does it Exist and How to Measure it?. 2009 , 3, 77-91	4
242	Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). 2010 , 37, 262-75	9
241	Acute coronary syndrome (unstable angina and non-ST elevation MI). 2009 , 2009,	5
240	Diabetes & coronary heart disease: current perspectives. 2010 , 132, 584-97	27

239	Assessment of clopidogrel on the left ventricular ejection fraction in acute myocardial infarction. 2010 , 1, 257-9	1
238	Surveying the medical literature: five notable articles in general internal medicine from 2008 and 2009. 2010 , 4, e181-6	2
237	Treatment of refractory angina. 2009 , 9, 220-6	2
236	Hypertension in people with type 2 diabetes: Update on pharmacologic management. 2011 , 57, 997-1002, e347-53	35
235	Secondary prevention of ischaemic cardiac events. 2011 , 2011,	2
234	Non ST-elevation acute coronary syndrome. 2010 , 2010,	
233	The predicted impact of heart disease prevention and treatment initiatives on mortality in Lithuania, a middle-income country. 2011 , 8, A139	2
232	Peripheral arterial disease. 2011 , 2011,	3
231	Optimal management of peripheral arterial disease for the non-specialist. 2011 , 80, 33-41	9
230	Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. 2010 , 1, 37-59	7
229	Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses. 2010 , 1, e0121	
228	Carotid artery stenting, endarterectomy, or medical treatment alone: the debate is not over. 2011 , 6, 1-13	
227	Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. 2013 , 59, 55-61	4
226	Management of Diabetic Nephropathy in the Elderly: Special Considerations. 2012 , 2,	
225	Prophylactic Add-on Antiplatelet Therapy in Chronic Kidney Disease With Type 2 Diabetes Mellitus: Comparison Between Clopidogrel and Low-dose Aspirin. 2013 , 4, 902-10	4
224	Effect of opium addiction on aspirin resistance in stable angina pectoris. 2014 , 6, 7-13	5
223	Sarpogrelate- another new antiplatelet agent?. 2012 , 62, 1253	
222	Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of north India. 2014 , 76, 504-9	2

221	Longitudinal analysis of meta-analysis literatures in the database of ISI Web of Science. 2015 , 8, 3559-65	3
220	Dual antiplatelet therapy for acute minor ischemic stroke or transient ischemic attack. 2015 , 3, 176	
219	Safety of thoracoscopic surgery for lung cancer without interruption of anti-platelet agents. 2015 , 7, 2024-32	11
218	A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass. 2010 , 42, 103-13	
217	Contemporary Management of Coronary Artery Disease and Acute Coronary Syndrome in Patients with Chronic Kidney Disease and End-Stage Renal Disease. 2013 , 29, 132-41	6
216	Biochemical aspirin resistance in stroke patients - a cross-sectional single centre study. 2013 , 12, 907-15	4
215	Therapeutic Targets for Management of Periodontitis and Diabetes. 2016 , 22, 2216-37	12
214	Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalicylic Acid Resistance. 2016 , 32, 321-7	1
213	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. 2017 , 19, D163-D189	
212	Unusual presentation of extensive spontaneous coronary dissection: Case report and literature review. 2017 , 13, 46-49	
211	Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome. 2017 , 14, 442-456	6
210	Specifications of Clinical Quality Measures and Value Set Vocabularies Shift Over Time: A Study of Change through Implementation Differences. 2017 , 2017, 575-584	2
209	Aspirin and Clopidogrel Resistance. 2004 , 15, 58-60	
208	Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis. 2004 , 25, 714-9	72
207	Spontaneous improvement of persistent ulceration after carotid artery stenting. 2006 , 27, 151-6	8
206	The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis. 2006 , 27, 1505-7	8
205	A meta-analysis of the correlation between non-steroidal anti-inflammatory drugs and recurrent colorectal adenomatous polyps. 2021 , 13, 2432-2438	
204	Severe bleeding following off-pump coronary artery bypass grafting: predictive factors and risk model. 2021 , 18, 449-461	0

203	Risk factors and pharmacological therapy in patients with vascular disease. 2022 , 11-24	
202	Acute stroke and transient ischaemic attack. 175573802110587	
201	Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review. 2021 ,	0
200	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 ,	39
199	Diagnosis and management of acute coronary syndromes.. 2021 , 44, 180-184	
198	Management of stable coronary artery disease and atrial fibrillation with anti-thrombotic therapy: A systematic review and meta-analysis.. 2021 , 100, e27498	1
197	Additional Effects of Antiplatelet Therapy on Anticoagulant Agents in Patients With Bioprosthetic Valves and Atrial Fibrillation. 2021 ,	0
196	Efficacy and safety of tirofiban bridge as an alternative to suspension of dual antiplatelet therapy in patients undergoing surgery: a systematic review.. 2021 , 20, e20210113	1
195	Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease. 2021 , 12, 97-103	
194	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2021 ,	42
193	Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro. 2021 , 106, 2874-2884	1
192	[Key aspects of drug therapy in vascular surgery].. 2021 , 27, 17-25	
191	Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.. 2022 , 9, 805525	2
190	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.. 2022 , 26, 1-128	2
189	Association of atherogenic serum lipids and platelet activation with changes in arterial stiffness in patients with type 2 diabetes. 2022 ,	0
188	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. 2022 , 86,	3
187	The Clinical Features of In-Hospital Recurrence in Acute Ischaemic Stroke Patients over Time: A Real-World Observation at a Single Center.. 2022 , 12,	1
186	Oral antiplatelet therapy for acute ischaemic stroke.. 2022 , 1, CD000029	0

185	A Review of Antithrombotic Therapies for Patients with Chronic Peripheral Arterial Disease and after Revascularization.. 2022 , 33197211048596	
184	Research Progress on Prevention of Esophageal Stricture after Endoscopic Submucosal Dissection by Different Hormone Administration Routes. 2022 , 12, 252-258	
183	Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF- κ B Signaling Pathway.. 2021 , 12, 793107	2
182	Inpatient Management of Acute Stroke of Unknown Type in Resource-Limited Settings.. 2022 , STROKEAHA121037297	
181	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation.. 2022 , 61, 465	1
180	Sex-related differences in treatment and outcome of chronic limb-threatening ischaemia: a real-world cohort.. 2022 ,	4
179	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2021 , CIR0000000000001038	23
178	High on-treatment platelet reactivity to aspirin in patients after myocardial infarction.. 2022 , 147, 112618	0
177	Building your Peripheral Artery Disease Tool Kit: Medical Management of PAD in 2022.. 2022 ,	1
176	Early Anticoagulation in Acute Ischemic Stroke.. 2022 ,	
175	Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report.. 2021 , 49, 3000605211064391	1
174	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. 2021 , 22,	5
173	Overview of Peripheral Arterial Disease of the Lower Extremity. 2022 , 449-488	
172	[Modern strategies of antithrombotic therapy in patients with multifocal atherosclerosis].. 2022 , 122, 49-55	
171	Antithrombotic Therapy in Peripheral Arterial Disease:Risk Stratification and Clinical Decision Making.. 2022 ,	0
170	Prolonged Venous Thromboembolism Prophylaxis May Not Be Necessary for DIEP Flap Breast Reconstruction: A Tertiary Center's 10-Year Experience.. 2022 ,	0
169	Antiplatelet agents for chronic kidney disease.. 2022 , 2, CD008834	1
168	When and How to Combine Antiplatelet and Anticoagulant Drugs?. 2022 , 42, 73-79	0

- 167 The Evolution of Antiplatelet Therapy Following Percutaneous Coronary Interventions: a 40-Year Journey.. **2022**, 0
- 166 Oxycodone relieves permeability damage and apoptosis of oxygen-glucose deprivation/reoxygenation-induced brain microvascular endothelial cells through ras homolog family member A (RhoA)/ Rho-associated coiled-coil containing kinases (ROCK)/ myosin light chain 2 (MLC2) signal.. **2022**, 13, 5205-5215 2
- 165 Non-Arteritic Anterior Ischemic Optic Neuropathy: Challenges for the Future. **2022**, 2,
- 164 Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: A long-term nationwide study.. **2022**,
- 163 Clopidogrel Versus Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.. **2022**, 101174
- 162 Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy.. **2022**, 13, 127-142
- 161 P2Y12 Inhibitor versus Aspirin Monotherapy for Secondary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Trials. 0
- 160 Blood Pressure Lowering for the Secondary Prevention of Stroke. **2022**, 2, 51-57
- 159 Does the ISCHEMIA Trial Apply to My Patients?. **2022**, 1
- 158 Analysis of the relationship between sex and prescriptions for guideline-recommended therapy in peripheral arterial disease, in relation to 1-year all-cause mortality: a primary care cohort study.. **2022**, 12, e055952 1
- 157 Sex-Specific Differences in Cardiovascular Risk, Risk Factors and Risk Management in the Peripheral Arterial Disease Population.. **2022**, 12, 0
- 156 Effect of anticoagulant/antiplatelet therapy on the development and progression of diabetic retinopathy.. **2022**, 22, 127
- 155 Aspirin in COVID-19: Pros and Cons.. **2022**, 13, 849628 1
- 154 Drug-Related Problems in Coronary Artery Diseases.
- 153 Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine.. **2022**, 13, 2
- 152 Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.. **2022**,
- 151 DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm.. **2022**,
- 150 Randomized controlled trial of early endoscopy for upper gastrointestinal bleeding in acute coronary syndrome patients.. **2022**, 12, 5798 0

- 149 Platelet reactivity testing in peripheral artery disease.. **2022**, 0
- 148 Investigating the predictive value of microRNA21 as a biomarker in induced myocardial infarction animal model. **2022**, 27, 101578 0
- 147 Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?. **2021**, 26, 4734 1
- 146 Primary and Secondary Prevention of CAD: A Review.. **2022**, 31, 16-26
- 145 Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.. **2021**, 1
- 144 Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases.. **2021**, 12, 794417 0
- 143 Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.. **2021**, 9,
- 142 Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated Pan-Canadian Cross-sectional Study.. **2021**,
- 141 Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease.. **2021**, 8, 773214 1
- 140 FactFinders for patient safety: Antithrombotics and interventional pain procedures -- lumbar transforaminal epidural steroid injections and lumbar medial branch radiofrequency neurotomy. **2021**, 1, 100008 1
- 139 Should Antiplatelet Therapy Be Withheld Perioperatively? The First Study Examining Outcomes in Patients Receiving Dual Antiplatelet Therapy in the Lower Extremity Free Flap Population.. **2022**, 149, 95e-103e
- 138 Genetic Profile-Guided Therapy for Stroke?. **2021**, 385, 2576-2577 0
- 137 STUDY THE FUNCTIONAL ACTIVITY OF PLATELETS AGAINST THE BACKGROUND OF ANTIPLATELET THERAPY IN PATIENTS OF THE CARDIOLOGICAL HOSPITAL. 20-29
- 136 The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. **2021**, 0
- 135 Social Deprivation and Peripheral Artery Disease.. **2021**, 0
- 134 Effect of anti-platelet therapy on peri-operative blood loss in patients undergoing off-pump coronary artery bypass grafting.. **2022**, 25, 182-187
- 133 Low-Dose Aspirin Augments the Anti-Inflammatory Effects of Low-Dose Lithium in Lipopolysaccharide-Treated Rats. **2022**, 14, 901 1
- 132 Medical Optimization of the PAD Patient. **2022**, 35, 113-113

- 131 Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.. **2022**, 23, 331 0
- 130 Guíā ESC 2021 sobre la prevenciā de la enfermedad cardiovascular en la prātica clāica. **2022**, 1
- 129 Monitoring skills. 86-106
- 128 Rehabilitation of dementia. 509-534
- 127 Use of Antiplatelet Drugs in Secondary Prevention in Patients With Atherothrombotic Disease. **2006**, 32, 182-188
- 126 Image_1.tif. **2019**,
- 125 Image_2.tif. **2019**,
- 124 Image_3.tif. **2019**,
- 123 Table_1.xls. **2019**,
- 122 Table_2.docx. **2019**,
- 121 Table_3.docx. **2019**,
- 120 Table_4.docx. **2019**,
- 119 A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control.. **2021**, 20, 238 1
- 118 Safety and outcomes of intravitreal aflibercept in diabetic macular edema - a systematic review.. **2022**, 1
- 117 OUP accepted manuscript.
- 116 Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. **2022**, 1, 105-110
- 115 The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects. **2022**, 1, 1-2
- 114 Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines.. **2022**, 13, 878416 0

113	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. 2022 , 21, 3235	11
112	Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19.. 2022 , 17, e0267462	1
111	Assessment of the appropriateness of cardiovascular preventive medication in older people: using the RAND/UCLA Appropriateness Method.. 2022 , 22, 394	
110	Do drugs interact together in cardiovascular prevention? A meta-analysis of powerful or factorial randomized controlled trials. 2022 ,	0
109	Optimal conduit choice for open lower extremity bypass in critical limb threatening ischemia. 2022 , 35, 172-172	
108	Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease.. 2022 , 38, 560-587	0
107	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management.. 2022 , 21, 74	1
106	Part 5: Acute Coronary Syndromes. 2005 , 112,	2
105	Which therapy for which condition?. 2013 , 463-541	
104	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. 2013 , 332-397	1
103	ADEQUATE ANTITHROMBOTIC THERAPY: REDUCTION OF MORTALITY BY THE RESULTS OF INTERNATIONAL CLINICAL TRIALS (literature review). 2013 , 22-29	
102	Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.. 2022 ,	
101	Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.. 2022 ,	0
100	Analysis of Adverse Reactions of Aspirin in Prophylaxis Medication Based on FAERS Database. 2022 , 2022, 1-8	0
99	Gender Disparities in Aorto-iliac Revascularization in Patients with Aortoiliac Occlusive Disease. 2022 ,	0
98	High on-treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A meta-analysis.	
97	Small Intestinal Perforation Caused by Enteric-coated Low-dose Aspirin: A Case Report. 2022 ,	0
96	Other Antithrombotics: Antiplatelets and Fibrinolytics. 2022 , 347-361	

- 95 Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease. **2022**, 17, 100152
- 94 Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study.
- 93 Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease. 13,
- 92 Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ○
- 91 Cerebral small vessel disease and intracranial bleeding risk: prognostic and practical significance. 17474930221d060
- 90 Development of a Carotid Artery Thrombolysis (iCAT) Stroke Model in Mice.
- 89 Resumption of Antiplatelet Therapy after Major Bleeding.
- 88 Immigration status and utilization of secondary preventive treatment after ischemic stroke. 239698732211118○
- 87 Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. **2022**, 2022, ○
- 86 Outcomes of Hospitalized Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) With and Without a History of Peripheral Artery Disease. **2022**,
- 85 Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women. ○
- 84 Aspirin for Primary Prevention of Cardiovascular Diseases: [WALTZ](#) with the Evidence.
- 83 Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. **2022**, ○
- 82 Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum. **2022**, 7, 64-69
- 81 Stroke pathway [An evidence base for commissioning](#) [An evidence review for NHS England and NHS Improvement](#). 2, 43
- 80 Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. **2022**, 82, 1165-1177 ○
- 79 Predictors of long-term medication adherence in stroke survivors: A multicentre, prospective, longitudinal study.
- 78 Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study. 13,

77	Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing. 2022 , 17, e0268905	
76	A Case Series Analysis of Major Vascular Revascularization. 2022 ,	
75	A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT _{2A} Receptor Inhibits Platelet Function. 2022 , 23, 8794	1
74	CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). 2022 ,	0
73	The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack. 1-15	0
72	Antiplatelet therapy after acute ischemic stroke or transient ischemic attack.	
71	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.	1
70	The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study.	1
69	Medical Therapy in Patients Managed in a Chest Pain Observation Unit. 2022 , 127-133	0
68	Nursing Assistance To The Patient With Acute Myocardial Infarction; Nursing Implications. 55-68	0
67	Venous Thromboembolism and Risk of Cancer in Users of Low-Dose Aspirin: A Danish Population-Based Cohort Study. 2022 , 06, e257-e266	0
66	Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. 2022 , 23, 11317	0
65	Prevalence and incidence of stroke, white matter hyperintensities, and silent brain infarcts in patients with chronic heart failure: A systematic review, meta-analysis, and meta-regression. 9,	1
64	Reaching a Tipping Point for Neurorehabilitation Research: Obstacles and Opportunities in Trial Design, Description, and Pooled Analysis. 154596832211241	0
63	Verifynow P2Y ₁₂ PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study.	0
62	Personalized allocation of acetylsalicylic acid therapy for secondary prevention of coronary artery disease. 9,	0
61	Smartphone App in Stroke Management: A Narrative Updated Review. 2022 , 24, 323-334	0
60	The Relationship between Atrial Fibrillation and Coronary Artery Disease: Understanding common denominators. 2022 ,	0

59	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. 2022 , 11, 5605	○
58	Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis. 13,	1
57	Fifty Years with Aspirin and Platelets.	○
56	Preeclampsia: Maternal cardiovascular function and optimising outcomes. 2022 , 174, 105669	○
55	Vagus nerve stimulation paired with rehabilitation for stroke: Implantation experience from the VNS-REHAB trial. 2022 , 105, 122-128	○
54	Pharmacologic Interventions in Patients with Peripheral Arterial Disease. 2022 , 67-79	○
53	The risk of aspirin induced postoperative hemorrhage: a systematic review and meta-analysis. 1-12	○
52	Antithrombotic therapy in peripheral arterial disease. 9,	○
51	Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial.	○
50	Evaluation of the efficacy of aspirin combined with low doses of clopidogrel in the treatment of symptomatic intracranial artery stenosis in the elderly.	○
49	Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. 2022 , 22, 789-802	○
48	Spotlight on clinical strategies of Chronic Internal Carotid Artery Occlusion: Endovascular interventions and external-intracarotid bypasses compared to conservative treatment. 9,	○
47	Pathophysiology, Diagnosis and Treatment of Spontaneous Coronary Artery Dissection in Peripartum Women. 2022 , 11, 6657	○
46	Cannulation and Decannulation Techniques for Neonatal ECMO. 2022 , 101404	○
45	A Case Report of the Hemostatic Effect of Samchilgeun Powder (Panax Motoginseng) on Hematuria in a Patient Requiring Double Antiplatelet Therapy Due to Recurrent Cerebral Infarction. 2022 , 43, 909-917	○
44	The Role of Pharmacists in Providing Pharmaceutical Care in Primary and Secondary Prevention of Stroke: A Systematic Review and Meta-Analysis. 2022 , 10, 2315	○
43	Difficulties and prospects of rational therapy of ischemic strokes. 2022 , 29-34	○
42	Antithrombotische Therapie bei pAVK und Aortenerkrankungen. 2022 , 11, 560-564	○

- 41 Aspirin for primary prevention of cardiovascular disease in women. **2022**, Publish Ahead of Print, ○
- 40 Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. **2023**, 34, ○
- 39 Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice Insights From the CANHEART Study. **2022**, 11, ○
- 38 Antiplatelet Therapy in Coronary Artery Disease: Now and Then. ○
- 37 Acetylsalicylic Acid Primus Inter Pares in Pharmacology. **2022**, 27, 8412 ○
- 36 Non-acute chest pain in primary care; referral rates, communication and guideline adherence: a cohort study using routinely collected health data. **2022**, 23, ○
- 35 Regulatory Effects of Curcumin on Platelets: An Update and Future Directions. **2022**, 10, 3180 ○
- 34 Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Bypass Surgery with Venous and Prosthetic Conduits. **2022**, ○
- 33 Gout Flare and Cardiovascular Events Reply. **2023**, 329, 96 ○
- 32 Management of Antiplatelet Therapy During Acute Percutaneous Coronary Intervention: New Strategies and Therapeutics. **2010**, 39, 221-229 ○
- 31 Antiplatelet Drugs in COVID-19: Mechanism of Action and Effect on Prognosis. **2022**, 331-349 ○
- 30 Peripheral Artery Disease (PAD). **2023**, 183-191 ○
- 29 Antithrombotic therapy in patients with diabetes mellitus. **2023**, 24, 737-750 ○
- 28 Anti-Aggregation and Antioxidant Properties of a New Derivative of Acetylsalicylic Acid and Carnosine. **2022**, 16, 472-479 ○
- 27 Experience of the use of dipyridamole for secondary prevention of ischemic stroke. **2023**, 42-48 ○
- 26 Risk Factor Profile and Treatment Patterns of Patients with Atherothrombosis in Singapore: Insight from the REACH Registry. **2008**, 37, 365-371 ○
- 25 A Comprehensive Review: Epidemiological Strategies, Catheterization and Biomarkers used as a Bioweapon in Diagnosis and Management of Cardio Vascular Diseases. **2023**, 48, 101661 ○
- 24 Aspirin Therapy, Cognitive Impairment, and Dementia A Review. **2023**, 3, 144-161 ○

- 23 Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China. 10,
- 22 L'aspirine a-t-elle une place dans la pr vention cardiovasculaire primaire par la polypill?  tude de simulation sur une population virtuelle r aliste. 2023,
- 21 A two-decade population-based study on the effect of hypertension in the general population with obesity in the United States. 2023, 31, 832-840
- 20 Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. 2023, 15, 549
- 19 Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. 2023, 16, 332-343
- 18 A recent experience on the role of influenza vaccination on cardiovascular events. 2023, 25, A31-A35
- 17 High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-Aspirin and Platelet Inhibition (ISAR-ASPI) Registry.
- 16 Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease. 2023, 28,
- 15 THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). 2009, 12-18
- 14 Akute Isch mie bei Tumorpatienten: Pathogenese, Therapie und Pr vention. 2023, 10, 59-70
- 13 Efficacy and safety of low dose aspirin plus clopidogrel in the treatment of elderly patients with symptomatic intracranial artery stenosis. 14,
- 12 Effect of perioperative aspirin continuation on bleeding after pneumonectomy.
- 11 Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. 2005, 94, 889-891
- 10 Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study. 2023, 371, 54-60
- 9 Subdural hygroma and hemorrhagic conversion after microsurgical clipping for unruptured intracranial aneurysm.
- 8 Effects of Combined Use of Salbutamol/Budesonide in Thoracic Surgery on Postoperative Myocardial Injury (MINS)   Prospective Randomized Clinical Trial. Volume 17, 1025-1036
- 7 Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?. 1-5
- 6 Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.

- 5 Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed. **2023**, ○
- 4 Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach. 15, 142-153 ○
- 3 Acute chest pain—diagnostic accuracy and pre-hospital use of anticoagulants and platelet aggregation inhibitors. ○
- 2 Inhibition of platelet aggregation (Update 2023). **2023**, 135, 161-163 ○
- 1 Optimal Medical Management in Patients undergoing Peripheral Vascular Interventions for Chronic Limb Threatening Ischemia is associated with Improved Outcomes. **2023**, ○